Phase IIb TLPLDC & TLPO vaccine trial  Version 2.4/ 15 February 2021  
Confidential  1 Protocol Title: A prospective, randomized, blinded, placebo -
controlled, phase IIb trial of an autologous 
tumor lysate (TL) + yeast cell wall particles 
(YCWP) + dendritic cells (DC) vaccine vs 
unloaded YCWP + DC and embedded phase 
I/IIa trial with tumor lysate particle onl y (TLPO) 
vaccine in stage III and stage IV (resected) 
melanoma to prevent recurrence.  
Protocol Number:  20141932  
Study Drugs:  Autologous TLPLDC vaccine (tumor lysate,  
particle -loaded, dendritic cells)  
and 
Autologous TLPO (tumor lysate, particle only)  
Sponsor:  Elios Therapeutics, LLC  
Director:  George E. Peoples, MD , FACS  
Cancer Insight, LLC  
1305 East Houston Street  
San Antonio, T exas  7820 5 
IND:  TLPLDC IND#16101  & TLPO IND# 17274  
Principal Investigator: Mark B. Faries, MD, FACS  
Head, Division of Surgical Oncology  
Co-Director, Melanoma Program  
Surgical Director, Experimental Therapeutics  
The Angeles Clinic  and Research Institute, a 
Cedars -Sinai Affiliate  
11818 Wilshire Blvd., Suite 220  
Los Angeles, CA 90025  
Medical Monitor :   Vance Sohn, MD  
Protocol Version/Date:  2.4/ 15 February  2021 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  2 Table of Contents  
1.0 PROTOCOL SYNOPSIS  ................................ ................................ .......................  4 
2.0 INTRODUCTION  ................................ ................................ .............................  10 
2.1 Immunotherapy in Melanoma  ................................ ................................ ................................ ..........  10 
2.2 Dendritic Cell Vaccines  ................................ ................................ ................................ ........................  12 
2.3 New Vaccine Technology  ................................ ................................ ................................ ....................  13 
2.4 Prior/Ongoing Clinical Trials with Autologous Tumor/DC Vaccine  ................................  16 
3.0 OBJECTIVES  ................................ ................................ ................................ ... 21 
3.1 Primary Objective  ................................ ................................ ................................ ................................ .. 21 
3.2 Secondary Objectives  ................................ ................................ ................................ ...........................  21 
3.3 Exploratory Objectives  ................................ ................................ ................................ ........................  21 
4.0 STUDY DESIGN  ................................ ................................ ...............................  22 
4.1 Description of Study  ................................ ................................ ................................ .............................  22 
4.2 Rationale for Study Design  ................................ ................................ ................................ .................  24 
4.3 Outcome Measures  ................................ ................................ ................................ ................................  25 
4.3.1  Primary outcome measures  ................................ ................................ ................................ ..................  25 
4.3.2  Secondary outcome measures  ................................ ................................ ................................ .............  26 
4.3.3  Exploratory outcome measures  ................................ ................................ ................................ ..........  26 
4.4   Safety Considerations ................................ ................................ ................................ ...........................  27 
4.5   Compliance with Laws and Regulations  ................................ ................................ .......................  28 
5.0   MATERIALS AND METHODS  ................................ ................................ ...........  28 
5.1 Subjects  ................................ ................................ ................................ ................................ ......................  28 
5.1.1  Subject selection  ................................ ................................ ................................ ................................ ........ 28 
5.1.2  Inclusion criteria  ................................ ................................ ................................ ................................ ....... 29 
5.1.3  Exclusion criteria ................................ ................................ ................................ ................................ ....... 30 
5.2 Method of Treatment Assignment  ................................ ................................ ................................ .. 31 
5.3 Study Treatment ................................ ................................ ................................ ................................ ..... 31 
5.3.1  Vaccine production  ................................ ................................ ................................ ................................ ... 31 
5.3.2  Storage  ................................ ................................ ................................ ................................ ...........................  32 
5.3.3  Inoculation series – administration  ................................ ................................ ................................ .. 33 
5.3.4  Dose reduction for TLPO  ................................ ................................ ................................ ........................  33 
5.4 Study Assessments  ................................ ................................ ................................ ................................  33 
5.4.1  Pretreatment assessments  ................................ ................................ ................................ ....................  34 
5.4.2  Assessments during treatment  ................................ ................................ ................................ ............  34 
5.4.3  Follow -up assessments  ................................ ................................ ................................ ............................  35 
5.4.4  Blood collection and processing  ................................ ................................ ................................ .........  36 
5.4.5  Phenotypic assay (for example, dextramer assay) for melanoma -specific antigens  . 36 
5.4.6  Functional assay (for example, ELISPOT assay) for melanoma -specific antigens  ..... 37 
5.5 Discontinuation of Protocol -Specific Therapy  ................................ ................................ ...........  37 
5.6 Subject Discontinuation  ................................ ................................ ................................ ......................  37 
5.7 Study Discontinuation ................................ ................................ ................................ ..........................  38 
5.8 Data Collection  ................................ ................................ ................................ ................................ ........  39 
5.9 Statistica l Methods  ................................ ................................ ................................ ................................  39 
5.9.1  Rationale for study design  ................................ ................................ ................................ ....................  39 
5.9.2  Sample size determination  ................................ ................................ ................................ ...................  40 
5.9.3  Data analysis  ................................ ................................ ................................ ................................ ...............  40 
5.9.4  Withdraw al ................................ ................................ ................................ ................................ ..................  43 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  3 5.9.5  Missing data  ................................ ................................ ................................ ................................ .................  43 
6.0 ADVERSE EVENTS  ................................ ................................ ...........................  43 
6.1 Adverse Event and Reporting Definitions  ................................ ................................ ...................  43 
6.2  Reporting of Adverse Events Associated with This Study  ................................ ....................  44 
6.3 Reporting Requirements for IND Sponsor  ................................ ................................ ..................  45 
6.3.1  MedWatch 3500A reporting guidelines  ................................ ................................ ..........................  45 
7.0 INVESTIGATOR REQUIREMENTS  ................................ ................................ ..... 46 
7.1  Study Initiation  ................................ ................................ ................................ ................................ ....... 46 
7.2  Study C ompletion ................................ ................................ ................................ ................................ ... 47 
7.3  Informed Consent  ................................ ................................ ................................ ................................ .. 47 
7.4 Institutional Review Board or Ethics Committee Approval  ................................ .................  47 
7.5 Study Monitoring Requirements  ................................ ................................ ................................ ..... 48 
7.6 Data Safety Monitoring Plan  ................................ ................................ ................................ ..............  49 
7.7  Study Medication Accountability  ................................ ................................ ................................ .... 49 
7.8  Disclosure of Data  ................................ ................................ ................................ ................................ .. 49 
7.9  Retention of Records  ................................ ................................ ................................ ............................  49 
7.10  Publications  ................................ ................................ ................................ ................................ ..............  49 
7.11  Changes to Protocol  ................................ ................................ ................................ ..............................  50 
REFERENCES  ................................ ................................ ................................ .............  51 
Appendix A  ................................ ................................ ................................ ...............  57 
Appendix B  ................................ ................................ ................................ ...............  58 
Appendix C  ................................ ................................ ................................ ...............  59 
Appendix D  ................................ ................................ ................................ ...............  61 
Appendix E  ................................ ................................ ................................ ...............  62 
Appendix F ................................ ................................ ................................ ................  63 
Appendix G  ................................ ................................ ................................ ...............  69 
Appendix H  ................................ ................................ ................................ ...............  71 
Appendix I  ................................ ................................ ................................ ................  72 
Appendix J  ................................ ................................ ................................ ................  73 
Appendix K  ................................ ................................ ................................ ...............  74 
 
 
 
 
 
  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  4 1.0 PROTOCOL SYNOPSIS  
Brief Title  A prospective, randomized, blinded, placebo -controlled, phase IIb trial of an 
autologous tumor lysate (TL) + yeast cell wall particles (YCWP) + dendritic cells 
(DC) vaccine vs unloaded YCWP + DC  and embedded phase I/IIa  trial in tumor 
lysate particle only (TLPO) vaccine  in stage III and stage IV (resected) melanoma 
to prevent recurrence.  
Test Article  Name  Autologous TLPLDC vaccine (tumor lysate, particle loaded, 
dendritic cells)  
Autologous TLPO vaccine (tumor lysate, pa rticle only)  
Activity  Induction of anti -cancer cell -mediated immune response  
Dosage form  Intradermal injection of 1 -1.5x106 autologous TLPLDC or 1.0x108 
TLPO  monthly x 3 followed by boosters at 6, 12, and 18 months  
Development 
Phase  Phase IIb  (with embedded phase I/IIa)  
Indication  To prevent recurrences in disease -free stage III and stage IV (resected) 
melanoma patients  
Rationale  Setting:  
Melanoma is a potentially lethal skin malignancy.  Patients with stage III and IV 
(resected) melanoma have a significant risk of recurrence in the 50 -90% range.  
Once recurrent, these patients will likely die of disease due to the paucity of 
effective systemic therapies . 
Melanoma is an immunogenic cancer often eliciting an endogenous immune 
response; however, if this protective mechanism fails then the disease progresses.  
Multiple immunotherapies have been tested in melanoma attempting to reinstate 
this immune protectio n.  Some of the immunotherapies which have shown promise 
have been cytokine therapies (IFN -α, IL-2) as mel anoma is an immunogenic cancer 
often eliciting an endogenous immune response; however, if this protective 
mechanism fails then the disease progresses.   Multiple immunotherapies have 
been tested in melanoma -PD-L1 antibodies have shown significant promise with 
the FDA approval of the former in the metastatic setting.  
While these FDA -approved immunotherapies are effective in a small percentage of 
melanoma patients, they are non -specific, often toxic, and poorly tolerated.  
Vaccines are meant to raise a more specific, tumor -targeted immune response with 
minimal toxicity.   Unfortunately, the majority of melanoma vaccines have been 
tested in late -stage patients with substantial tumor burden and have shown minimal 
benefit.  Current data suggests that the best time to intervene with a vaccine 
strategy is in the adjuvant setti ng after patients have been rendered disease -free 
by standard of care (SoC) therapies.  In this setting, the vaccine -induced immune 
response can attack any minimal residual disease and hopefully provide long -term 
protection through immunologic memory with minimal toxicity.   
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  5 Rationale  
(continued)  Vaccine:    
The majority of  melanoma vaccines tested to date have been antigen -specific 
vaccines targeting melanoma -specific or associated antigens and utilizing a variety 
of delivery systems and immune -adjuvants.  As opposed to testing an “off the shelf” 
vaccine that might be able to treat a subset of patients, our approach has been 
personalized to the patient and applicable to all patients.  Our vaccine approach 
consists of harnessing the most potent antigen presenting cell in the body  – the 
dendritic cell (DC ) – together with the full repertoire of tumor antigens from an 
individual’s cancer.  We have conducted phase I and II studies using an autologous 
DC-tumor cell fusion technique that has now been simplified into a DC -tumor cell 
lysate vaccine.  The autologous tumor lysate (TL)  is loaded into yeast cell wall 
particles (YCWP) that are naturally and efficiently taken up into the patient’s DC.  
These autologous tumor lysate, particle -loaded, DC (TLPLDC) are injected 
intradermally (ID) monthly x 3 followed by boosters at 6, 12, and 18 months.  
The embedded phase I/IIa  will introduce the next version of the vaccine, which 
simplifies the production process. It utilizes the autologous tumor to create the 
tumor lysate, which is then loaded into the yeast cell wall particles and then cappe d 
with silicate  for stability. This tumor lysate, particle only (TLPO)  vaccine , is then 
injected intradermally and taken up in vivo  by dendritic cells and stimulates the 
patient’s immune system to recognize the tumor. These autologous TLPO vaccines 
are inj ected in the same manner as the TLPLDC, monthly x3 followed by booster 
at 6, 12, and 18 months.  
Prior Results:  
To date , we have vaccinated a total of 36  patients w ith varying malignancies, and 
25 of these have been late -stage melanoma patients.  The se personalized vaccines 
have a very favorable toxicity profile with only flu -like symptoms immediately after 
inoculations, and no related serious adverse events have been observed  in any 
patient vaccinated to date .  In the completed phase I/IIa melanoma trial, 2 5 stage 
IV patients were vaccinated.  The median overall survival (OS) was 14.5 months 
(compared to a historic rate of 8.5 months), and there was a 27% OS at 3 yrs.  
There was a dose response with an OS improvement in patients receiving ≥3 
inoculations com pared to patients receiving less (log rank p=0.025).  Additionally, 
among the small group of stage IV (resected) patients (n=4), the OS was 100% at 
20 months median follow -up.  
Primary 
Endpoint  For the TLPLDC phase IIb:  
To determine 24-month disease -free survival (DFS) in vaccinated  (TLPLDC ) vs 
control patients.  
For the TLPO phase I/IIa:  
To assess the safety of the vaccine per CTCAEv4.03  
Secondary 
Endpoints  For the TLPLDC phase IIb:  
1) To determine DFS and OS at 36 months in vaccinated (TLPLDC) vs control 
patients.  
2) To document the safety of the vaccine.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  6 Exploratory 
Endpoints  For both trials:  
 1) To document immunologic response to the vaccine s through T -cell assays 
recognizing known melanoma -specific antigens.  
2) To correlate vaccine immune response to clinical outcome.  
3) To assess safety and tumor response of continued vaccination in combination 
with SoC therapies in patients after recurrence.  
Patient 
Population  Stage IIIA -C, Stage IV (resected) melanoma patients identified prior to definitive 
surgery and anticipated to be clinically disease -free after surgery.   
Treatment Arms  For the TLPLDC phase IIb:  
1) Vaccinated group = autologous tumor cell lysate + yeast cell wall particles + 
autologous DC  (TLPLDC)  
2) Control group = empty yeast cell wall particles + autologous DC  
For the TLPO phase I/IIa:  
1) Vaccinated group = autologous tumor cell lysate + yeast cell wall particles 
(TLPO)  
Stratification , 
Randomization , 
and Crossover  Patients will be stratified based on stage III vs stage IV.  
Randomization will be 2:1 ( vaccine: control).  
All patients will be  offered open label  active vaccine at first sign of recurrence . 
Non-recurrent c ontrol patients will be given the option of receiving active vaccine 
upon  their completion of the trial. 
Upon randomization of the 120th patient in the TLPLDC phase IIb, the TLPO 
phase I/I Ia trial will be initiated and 60 additional patients will be randomiz ed 2:1 
(TLPO  phase I/IIa :TLPLDC) .   
Number of 
Patients  At least N= 180 
Sample Size 
Justification  Assuming a baseline recurrence rate of 60% (corresponding to a DFS of 40%) at 2 
years in this mixed group of stage III and stage IV (resected) melanoma patients, a 
sample size of approximately  120 will have 80% power to detect a statistical 
difference between treatment  proportions  controlling the type I error at alpha = 0.05 
(two-sided).   
A blinded evaluation of the first 75 patients enrolled discovered an early recurrence 
rate of 12% prior to completion of primary vaccine series. To compensate for this 
early recurrence rate  and preserve the power of the trial, enrollment will be 
extended by at least an additional 20 patients, now totaling at least 140.  
The TLPO phase I/IIa will be assessed primarily for the tolerability of the TLPO 
vaccine as determined by CTCAEv4.03.  Additionally, immunologic assays will be 
assessed for vaccine induced T ce ll recognition of common melanoma -related 
antigens.  Patients will be followed clinically per standard of care for disease status.   
Number of Sites  10-12 sites will be established.  
Duration of Trial  With 10-12 sites enrolling at 0.8 pts/site/month, we anticipate enrollment to be 
complete in 12 -18 months.  With a primary endpoint of 2  year DFS and secondary 
endpoints of 3 y ear DFS/OS, the trial duration is expected to be 4 -4.5 y ears. 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  7 Trial Design  and 
Condu ct Stage III and Stage IV (resected) melanoma patients will be identified prior to definitive 
surgery and screened for inclusion/exclusion criteria.  Eligible patients will be counseled 
and consented for tissue procurement.  Enrolled patients will have their disease 
surgically resected and a portion (1mg  minimum ) of their melanoma sterilely frozen in 
provided  freezing vials and storage tubes.  This tissue will be shipped in liquid nitrogen 
shippers through FedEx to our central facility in Greenville, SC and stored frozen until 
vaccine preparation.  If patients cannot be rendered disease -free, they will be 
considered screen failures for this study.  If melanoma is being resected from multiple 
locations (primary and nodes, two different metastatic sites), t hen samples of each 
would be preferred but not mandatory.  
As indicated by SoC per the National Comprehensive Cancer Network ( NCCN ) 
guidelines and determined by the treating team, if a patient is to receive systemic 
therapy (chemotherapy or IFN α and/or radiation therapy ), then the vaccinations will not 
begin until SoC therapy is completed .  Although, patients on adjuvant check point 
inhibitors (CPI) may start the vaccine trial after showing tolerance of the CPI after 3 
doses,  given that there may a synergistic benefit and no added toxicity when adding the 
vaccine to CPI.  Once SoC therapies are complete (or demonstrating tolerance  on CP I 
after 3 doses ) and the patient deemed clinically disease -free, they will be consented for 
treatment and randomized.  Once consented, patients will receive a single injection  of 
Neupogen (G -CSF) 300 µg (or its equivalent) SQ 24 -48 hrs prior to having 70 mL of 
blood collected and  sent to our central facility for DC isolation and preparation.  Patients 
who cannot  tolerate Neupogen , or its equivalent  or refuse it, will have 120 mL of blood 
drawn and sent.   Additional blood may be drawn if additional vaccine doses need to be 
made or re -made for any reason. Vaccines will be prepared by producing TL through 
freeze/thaw cycling and then loaded into pre -prepared YCWP.  The TL -loaded YCWP 
will be introduced to the DC for phagocytosis thus creatin g the TLPLDC vaccine , which 
will be frozen in single dose vials.   Each vial will contain 1 -1.5 x 106 TLPLDC and will 
be labeled with the patient’s unique study number.  The TLPO is created in a similar 
manner with the freeze/thaw cycling, loaded into pre -prepared YCWP, and then capped 
with silicate for stability.  The TLPO vaccine is then frozen in single dose vials of 1.0 x 
108 TLPO and will be label ed with the patient’ s unique study number.  
Based on their randomization, autologous TLPLDC (active vaccine) or unloaded YCWP 
+ autologous DC (control) or autologous TLPO will be sent back to the site in a blinded 
fashion.  Upon randomization of the 120th patient the randomiza tion will transition to 2:1 
(TLPO  phase I/IIa :TLPLDC).  Regardless of assigned group, the site will receive 6 single 
dose vials to be injected intradermal monthly x 3 followed by boosters at 6, 12, and 18 
months in the same lymph node draining area (prefera bly the anterior thigh).  Patients 
must begin vaccinations between 3 weeks and 3 months from completion of SoC  (or 
demonstrating tolerance  on CPI  after 3 doses ).  Frozen tumor will be maintained for 
active vaccines for all patients to include the control patients.  The latter will be offered 
their active vaccine at time of recurrence in a crossover fashion.  Additionally, control 
patients who do not recur will be offered active vaccine at the completion of the trial.  
Safety data will be collected o n local and systemic toxicities and graded and reported 
per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03.  
Disease -free status will be monitored per SoC as outlined by NCCN.   Suspected 
recurrences will be documented with biopsy and patho logic confirmation.   Time to 
recurrence will be based on date of randomization to time of confirmed recurrence.   
Recurrent patients will be offered participation in the open label portion of the study.  
New active vaccine will be made for all patients, and  they will be inoculated at 0, 1, 2, 3, 
6, and 9 mos.  Patients will be treated per SoC for their recurrence.  Safety and tumor 
response will be assessed per RECIST and i RECIST  on their SoC follow -up scans.  
Blood (50 mL) will be collected from all patients  prior to each inoculation and at 24 
months from enrollment for a total of 7 time points or a total of 350 mL of blood over 2 
years.  The collected blood will be sent to our central facility f or immunologic testing of 
the T -cell response.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  8 Inclusion 
Criter ia 1) Stage IIIA -C patients identified prior to their definitive surgery  
2) Stage IV patients rendered clinically disease -free with surgery  
3) Approximately 1 cm3 is preferred (but 1 mg minimum)  of accessible and 
dispensable tumor that will not interfere with pathologic staging  
4) Clinically disease -free after SoC therapies  OR clinically disease -free after 3 
doses of CPI therapy, demonstrating tolerance of CPI, and completion of other 
SoC therapies  
5) ECOG 0 -1 performance  
6) Not involved in other clinical trials  
7) Capable of giving informed consent  
Exclusion 
Criteria  1) Evidence of residual disease after surgery and SoC therapies  
2) Insufficient tumor available  to produce vaccine  
3) Immun e deficiency disease or HIV, active HBV, or active HCV  
4) Steroids or other immunosuppressants  
5) ECOG >2 
Statistical 
Analysis  The primary endpoint for analysis of clinical efficacy is 2 4 mo nths DFS when 
analyzed as a proportion using Pearson chi-square test.  The intention -to-treat 
(ITT) population analyses and the per protocol (PP) population analyses will be co-
primary given the high early recurrence rate . 
In the time -to-event analysis, Kaplan -Meier curves will be generated to display 
time t o events for each treatment group.  
The null and alternative hypotheses are:  
H0: hV / hC = 1    
Ha: hV / hC ≠ 1  
where hV is the constant autologous TLPLDC vaccine hazard rate and hC is the 
constant unloaded YCWP + autologous DC control hazard rate. The activ e vaccine 
efficacy is demonstrated when hV / hC < 1; the alternative hypothesis is a 0. 50 
hazard ratio.  
The overall type 1 error rate of 5% will be used for the rejection of the null 
hypothesis in favor of the alternative hypothesis that autologous TLPLDC  or TLPO  
vaccine will prolong DFS over that of unloaded YCWP + autologous DC . 
The stratification factors are the following:  
Stage (III vs IV)  
The time -to-event analysis  efficacy analysis will be based on a proportional hazard 
model including the stratification factors to estimate the hazard ratio. Hazard ratios 
and 95% 2 -sided confidence intervals will be  presented. The model will also 
examine 2 -way treatment interaction s with the baseline stratification  factors.  
Confirmatory analyses will be performed using a stratified log rank test for each of 
the stratification  factors.  
Subgroup analyses will be displayed; any p -values for indivi dual strata will be 
regarded as descrip tive statistics.  
To explore the possibility of a treatment by investigative site interaction, the 
primary analysis will also  be conducted by site for the ITT and PP populations. 
Sites that have enrolled large numbers of  subjects relative to other trial cen ters will 
be identified to see if the results obtained at those  investigative sites are influential. 
Investigative sites that individually represent fewer than 10 subjects  will be 
combined for this exploratory analysis; geographic region will be substitute d if the 
average  number of subjects per site is fewer than 10.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  9 Planned 
Survival 
Analyses  1) The primary analysis will be conducted at the completion of two years of 
follow -up on the last enrolled patient and will compare 2 -year DFS between the 
two treatment arms.  
2) An interim analysis is planned six months after enrollment of the 120th patient .  
This analysis will compare median DFS between treatment groups.  
3) The secondary analysis will be conducted at the completion of 3 yrs. of follow -
up on the final enrolled patient and will compare 3 -year DFS and OS between 
treatment groups.   
 
  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  10 2.0 INTRODUCTION   
2.1 Immunotherapy in Melanoma  
Although melanoma is capable of eliciting an endo genous immunogenic response, 
the disease progresses when such protective mechanism fails.  After standard of 
care (SoC) therapy of stage III and IV melanoma, clinically disease -free patients 
have a 50 -90% risk of recurrence.  On ce recurrent these patients will likely die from 
their disease.  Currently, chemotherapy, radiation therapy and immunotherapy are 
the main choices for metastatic disease with the hope of prolonging survival1.  The 
majority of chemotherapy trials have been disappointing with no consensus 
standard therapy for care.  Overall, immunotherapy appears to be the most 
promising.  Even though immunotherapy has been studied for more than half a 
century as a treatment for cancer, recent advances in molecular immunology  now 
make this strategy a viable option for the treatment of patients with advanced 
cancers2.   
Several immunotherapeutic strategies have been studied as methods to re -instate 
the innate and adaptive immune responses in melanoma.  IFN -α and IL -2 
immunother apies are promising cytokine therapies having gained U.S. Food and 
Drug Administration ( FDA) approval for treatment of metastatic melanoma.  More 
recently, i pilimumab, a monoclonal antibody (mAb)  targeting CTLA -4, was 
approved by the FDA for use in the met astatic setting in 2011.  
IL-2 therapy is a common agent utilized in community practice despite its 
association with significant toxicities3-5.   Multiple phase II trials have evaluated IL -
2 therapy in conjunction with chemotherapy (cisplatin, vinblastine, dacarbazine, 
interferon -alpha, and IL -2), a treatment strategy with complete response rates of 
15-21% and overall response rates as high as 64%6-8 prompting FDA approval in 
1998.  A phase III trial evaluating biochemotherapy (cisplatin, vinblastine, 
dacarb azine, IL -2 and interferon alpha -2b) showed an increased response rate 
and progression -free survival in comparison to chemotherapy alone, but this was 
not associated with increased overall survival (OS) or improved quality of 
response9.  Subsequent meta -analysis also showed no survival benefit of 
biochemotherapy in metastatic melanoma despite an improved overall response 
rate10.  With toxicities of biochemotherapy substantially higher than chemotherapy 
alone, attempts to decrease this toxicity by administra tion of lower doses of IL -2 in 
the outpatient setting failed to show benefit of this approach vs chemotherapy 
alone11-13.  Additional synergistic toxicities between IL -2 and ipilimumab (discussed 
below) therapies are also being brought into question14. 
Interferon therapy has been shown to increase DFS but the impact on OS remains 
unclear14.  The World Health Organization conducted the initial major randomized 
trial examining low dose adjuvant interferon in resected stage III melanoma without 
an improvement in OS15.    
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  11 Two subsequent randomized studies in resected stage IIb/III melanoma also failed 
to show improvement in OS or recurrence -free survival16.   
However, in another prospective trial in stage II melanoma patients, DFS was 
increased by 41 months in the adjuvant interferon group17.  In an adjuvant trial by 
the French Cooperative Group, a significant relapse -free survival benefit and trend 
towards increased OS was noted in clinically node -negative patients with 
melanoma > 1.5 mm18.   A random ized trial by the Eastern Cooperative Oncology 
Group (ECOG 1684) examining high -dose interferon -α -2b has also shown 
significant improvement in relapse -free and OS at 6.9 months median follow -up in 
stage IIb and stage III melanoma; although, this effect la ter waned at 12.6 months 
median follow -up19 with a larger follow -up trial confirming the lack of OS survival 
advantage20.  A pooled analysis of the three randomized trials examining high dose 
interferon -α (E1684, E1690, and E1694) confirmed an improvement in relapse -fee 
survival in the high -risk melanoma population without improvement in OS21.  The 
FDA has since approved the adjuvant use of pegylated interferon -α in node -
positive melanoma patients based upon a significant 4 -year relapse -free survival 
benefi t (45.6% vs 38.9%) seen in a randomized trial of 1,256 patients with 
completely resected stage III melanoma22.   Yet, despite FDA approval the high 
toxicity of adjuvant high -dose interferon is causing decreased use in most 
institutions although most Nation al Comprehensive Cancer Network (NCCN) 
panelists agree on its role in specialized situations14.   
Ipilimumab gained FDA approval in the metastatic setting after a randomized 
phase II I trial revealed a significant OS advantage from gp100 and ipilimumab 
comb ination therapy or ipilimumab monotherapy compared to  gp100 
monotherapy23.  A significant OS benefit has been shown in a phase III trial of 
ipilimumab plus dacarbazine as well24.  Unfortunately, ipilimumab’s stimulation of 
T-cells may be associated with significant toxicity  with immune -related events 
occurring in 60% of patients from the gp100 and ipilimumab combination trial.  In 
this trial, 10 -15% of the  ipilimumab -associated  immune -related adverse events 
were severe ( grade 3 or 4 ) with immune -related toxicity attributed as the cause of 
seven  deaths.  As a T -cell stimulator, ipilimumab is specifically associated with 
significant risk of autoimmune reactions, and with the overall response rate 
occurring in less than 20% of patients, clinical effects often take months to become 
apparent.  However, when therapeutic responses occur, they are often sustainable 
raising questions of application in the adjuvant setting.  ECOG is currently 
conducting a prospective randomized trial of ipilimum ab vs IFN -α in the adjuvant 
setting to prevent recurrence in stage III melanoma25. 
Although ipilimumab represents the only FDA approved immunostimulatory mAb, 
promising results are being obtained from clinical trials examining the safety and 
efficacy of th e new programmed cell death protein 1 (PD -1)/programmed cell death 
ligand 1 (PD -L1) pathway blocking antibodies.  The PD -1/PD -L1 pathway has been 
increasingly utilized after being found to play an integral role in tumor -induced 
immunosuppression26, 27. Ant i-PD-1 and anti -PD-L1 agents are currently being 
tested in early clinical trials28.   
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  12 A recent phase I trial boasts rapid response with 31% of advanced melanoma 
patients reported to have an objective response at 8 weeks with a median OS of 
16.8 months for the total study population29. Noting the possible complementary 
role between CTLA -4 and PD -1, a phase I clinical trial cohort study examined this 
combination therapy with evidence of tumor regression in a substantial number of 
patients30. Given these resul ts, a phase 3 trial comparing CTLA -4/PD -1 to either 
agent alone is currently underway ([STUDY_ID_REMOVED])31. 
Although promising, setbacks of current therapies include the small percentage of 
melanoma patients in which efficacy is shown, lack of specificity, and high 
toxicities.  Although efficacious against some tumors, the potency of the above 
approaches is limited by their non -specific engagement of the host immune 
system.  An ideal strategy will utilize the full potential of the host immune system 
but in a spe cific/targeted manner.  As such, a tumor -targeted vaccine strategy is 
an appealing adjuvant strategy.  
2.2 Dendritic Cell Vaccine s  
Sipuleucel -T (Provenge ), an autologous  dendritic cell -based vaccine, is the only 
FDA-approved cancer vaccine.  The phase III trial examining Provenge’s three -
shot inoculation series improved OS by 4.1 months over placebo32 without toxicity 
leading to regulatory approval for use in patients wit h metastatic castration -
resistant prostate cancer in 201 0.   
Alone or in combination with cytokines, vaccines hold promise of eliciting a 
sustainable, more specific, tumor -targeted immune response with minimal toxicity.  
Several laboratories have demonstra ted that tumor cells persist in part because 
they have one or more mutations that allow escape of immune surveillance33-36.  
As exemplified by sipuleucel -T, dendritic cells can be used as professional an tigen -
presenting cells (APC)  to present tumor antigen s to the immune system in an 
attempt to overcome this escape.   
In order to stimulate robust anti -tumor immunity with activation of CD8+ T-cells, 
tumor antigens must be presented by APC in the context of MHC Class I 
molecules.  However, endocytosis of tumor antigens exposed to dendritic cells 
directs presentation by MHC Class II eliciting helper T -cells only , thus failing to 
engage the full power of the immune system with activation of a cyt otoxic T -
lymphocyte (CTL) response.   
Laboratori es have attempted to use gene transfer methods to introduce specific 
tumor antigens into dendritic cells from which they will be presented via MHC Class 
I37-41.  Unfortunately, numerous challenges include: 1) the inability to identify and 
map all integral tumor specific antigens ; 2) the limited number of known tumor 
antigen genes that can be introduced into the dendritic cell ; and 3) the complicated, 
time-consuming process required of this strategy.   
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  13 Given the potential disadvantages of specific antigen id entification, an ideal 
strategy involves inclusion of the entire content of tumor cells within the dendritic 
cells.  As a result, the entire portfolio of potential tumor antigens will be included 
within the APC.   Formation of a dendritic and tumor cell hy brid cell is one method 
to harness the DC with the full repertoire of tumor antigens from an individual’s 
cancer37, 42.  As such, it is an approach personalized to the patient while potentially 
available  to all patients.   Both peptide and tumor lysate -loaded dendritic cells have 
been previously utilized to vaccinate patients43-49.  A preferred method to 
manufacture a tumor cell/dendritic cell hybrid uses un -cultured, post -irradiation 
tumor cells to produce a non -proliferative hybrid cell or dendritoma that  retains 
both the character of the tumor cells in addition to the ability to act as an effective 
APC.  Animal studies have shown these hybrid cells capable of producing an anti -
tumor specific immune response50-58.  Results from in vitro studies 37, 59, 60 and 
human clinical trials42, 60 are also encouraging.  Scientists have observed that DC 
pulsed with tumor proteins can be administered repeatedly without side effects, 
suggesting the safety of DC -based vaccines.   
Drawbacks of this approach include the tim e consuming production process that 
makes application of a dendritoma  vaccine within the clinical setting difficult.  
Therefore, we developed a novel technique by which hybrid cells can be easily 
purified from a fusion mixture, instantly and without cultur e61.  Hybrid cells are 
instantly purified from these fusions between DC and tumor cells.  This process 
allows these dendritomas to retain the characteristics of the tumor cell as well as 
the ability of the DC to act as an effective APC. Animal studies have  confirmed that 
the purified dendritomas are better activators than fusion mixtures in stimulating 
specific anti -tumor immunity62.  With the hypothesis that the use of highly purified 
hybrid cells from DC -tumor cell fusion would be more effective than the entire 
fusion mixture in stimulating tumor cell -specific antitumor immunity, we examined 
this instant dendritoma  purification technique in a pilot study of ten stage IV renal 
cell carcinoma patients  and phase I and IIa  trials in stage IV melanoma patients .  
In combination with IL -2 therapy, dendritomas prepared from autologous DC and 
tumor cells were administered by subcutaneous injection.  With toxicities related 
to IL -2 therapy, the se studies showed both clinical and immunologic disease -
specific response s63. 
2.3 New Vaccine Technology  
Unfortunately, although injection of these dendritomas allows for effective 
presentation of tumor epitopes to patients’ immune system s to stimulate a CD8+ 
CTL anti -tumor response61, 62 sufficient tumor tissue is often unavailable to create 
a dendritoma  vaccine for most solid tumor patients.  
New technology whereby patients’ tumor cell lysate is loaded in to micro particles 
to be phagocytized by DC offers an alternative when sufficient tumor  tissue in not 
available.   
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  14 Reproducing the strong CD8+ immune response observed previously with the  
dendritoma vaccine s, this technology takes advantage of an immature DC’s avid 
phagocytosis of small particles in the range of 1 -5 microns.  Using a minimum 250 -
500 microgram sample of tumor tissue, it is repeatedly subjected to freeze -thaw 
cycling to create a tumor lysate su spension that is then loaded within the inner 
space of denatured yeast cell wall particles (YCWP).  These YCWP are then 
incubated with and are engulfed by immature DC.  These DC now contain tumor 
lysate within their cytoplasm , and tumor antigens are proces sed through the 
endogenous pathway.  These tumor antigen -loaded professional APC are the 
vaccine.  More specifically, t he YCWP  allow for the tumor proteins to  escape the 
lysosome and thus digestion,  so epitope products are not shuttled to the MHC 
Class II pathway.  Instead, these particles deliver protein tumor antigens into the 
cytoplasm where they are digested by the proteasome into epitopes that are then 
processed by TAP (transporter associated with antigen processing) and bound to 
MHC class I molecules in the endoplasmic reticulum.  In short, tumor lysate from 
the patient is loaded into YCWP , which are then phagocytized by patient dendritic 
cells.  These tumor lysate, particle -loaded DC (TLPLDC) are then administered as 
the vaccine.  
Theoretically, inject ion of this solid tumor vaccine intradermally near a lymph node 
allows the TLPLDC to effectively "present" the tumor epitopes to the patient's T -
cells and to stimulate the generation of antitumor immune responses.   
The next iteration  of the vaccine produc tion, TLPO, has removed the DC loading 
ex vivo and allows the DC to phagocytize the tumor lysate in vivo. The tumor lysate 
is produced in the same manner as TLPLDC with the autologous tumor tissue 
undergoing the freeze/thaw cycles and then loaded into the yeast cell wall 
particles. The TL -loaded YCWP are  then capped  with silicate to generate the 
TLPO vaccine . The TLPO vaccine removes the step s of harvesting the DC , 
maturing them , and loading the DC  ex vivo. The TLPO method allows the DC to 
be loaded in vivo and present the tumor epitopes.  
The concept of using TLPLDC as tumor -antigen -presenting cells in a therapeutic 
vaccine was initially tested in a murine metastatic melanoma model.  In these 
studie s, dendritic cells were prepared from mouse bone marrow and an 
established murine metastatic melanoma cell line was used as the source of the 
tumor cells.  The dendritic cells were loaded with YCWP containing B16F0 tumor 
lysate . Three days prior to the TLP LDC preparation, female C57BL/6J mice were 
challenged with B16F0 melanoma cells by intravenous injection.  Once the 
TLPLDC were prepared, each mouse in the treatment group was injected 
subcutaneously with TLPLDCs and this vaccination repeated for three wee kly 
doses.  The mice were monitored up to four weeks for pulmonary metastasis. At 
the end of four weeks, the mice were sacrificed and the metastases were counted.  
All four control animals that were not treated with TLPLDC had more than 50 
tumors.  On the other hand, none of the treated animals had measurable 
metastases.   This experiment has been replicated multiple times , and t hese data 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  15 indicate that TLPLDC are effective in treating cancer in a proven animal model 
system.   
The TLPO Investigator’s Brochure  details the specifics of the preclinical testing, 
but in summary, to  test the TLPO concept, first YCWP were loaded with 
fluorescence labeled albumin  and then half capped with silicate  and half left 
uncapped. These particles were shaken in solution and tes ted for fluorescence 
leak at 1 and 2 hours. The fluorescen ce leak experiment s demonstrated decreased 
leak from capped YCWP at 1 and 2 hours (15.8% vs 24.7% and 6.7% vs 16.6%, 
respectively).  Next, the capped and uncapped YCWP were added to cultured 
mouse m acrophage cells to evaluate DC uptake at 20 minutes, 1 hour and 2 hours; 
cells were then lysed and centrifuged to evaluate the amount of fluorescent 
material in the cytoplasm versus organelles. There was increased uptake of 
capped YCWP in DC cells compared  to uncapped, particularly at 2 hours after 
introduction (fluorescence readings of 11065 vs. 3928). Lysed DC loaded with 
capped YCWP demonstrated delivery of 68.9% of contents to the cytoplasm vs. 
48.8% in uncapped YCWP. Next, C57B mice were injected with 100ul saline  
(group  #1), 106 empty capped YCWP ( group  #2) or 1mcg murine GMCSF ( group  
#3). Five hours post -injection, 100ul saline was injected into the same site, then 
withdrawn, placed on a slide and examined under the microscope at 160X to 
evaluate the number of monocytic cells. The in vivo murine model showed greatly 
increased recruitment of monocytic cells in the m ice recei ving empty capped 
YCWP vs. GMCSF or saline alone. Then the TLPLDC vs TLPO was compared in 
a B16 melanoma model with mice followed to 80 days.  In this murine survival 
model, there was improved survival in those treated with TLPLDC or TLPO vs. 
controls .  
  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  16 Figure 1: Murine Survival Model TLPLDC vs TLPO vs Control  
 
Squares=TLPLDC, n=10  
Triangles=TLPO, n=20  
Circles=controls,  n=5 
 
Finally, in a large animal equine model, 4 grey horses with melanoma were treated 
with autologous TLPO created from a biopsy of their individual lesions, injected 
every 2 weeks for a total of 4 vaccinations.  The target lesions were assessed over 
6 months  by standard RECIST criteria . The equine model revealed one horse to 
be a complete responder (100% resolution of the target lesion) and the remaining 
3 as partial responders (50%, 68%, and 45% re duction in tumor size ). 
Through this series of results, the si licate capped TLPO particles have proven to 
be effective at retaining loaded  contents, have improved uptake by DC and, 
specifically, effective delivery to the cytoplasm of DC. In early animal studies, 
TLPO appears to have equivalent efficacy compared to th e TLPLDC vaccine, but 
eliminates the need for ex vivo DC loading.   The TLPO vaccine has not been used 
in humans previously, and as such, the TLPO portion of th is study is considered a 
first in man study and will be conducted as a phase I/IIa trial with saf ety, immune 
response and early clinical efficacy endpoints.  
2.4 Prior/Ongoing Clinical Trials with Autologous Tumor/DC Vaccine  
We have conducted phase I/II a clinical trials examining DC + autologous tumor 
vaccination of solid tumor patients in combination with IL -2.   To date, we have 
vaccinated 35 late -stage melanoma and renal cell carcinoma patients.  
In a phase I  trial (IND# 8851 ), ten patients with s tage IV melanoma received a 
vaccination every three months at a dose ranging from 500,000 -1,000,000 or more 
dendritomas.  IL -2 dose was increased from 3 MIU/m2/day if tolerated to a 
maximum dose of 9 MIU/m2/day for five days (administered one day after the first 

Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  17 dendritoma vaccine but not after subsequent vaccinations).  There were  two 
unrelated serious adverse events : one patient died due to progressive disease 19 
days after the first vaccination , and another  patient experienced thrombocytopenia 
that led to a s plenectomy 73 days after the last vaccination.  
The maximum level of toxicity experienced by the patient s in the phase I trial is 
depicted in Figure 1.  The most common adverse events experienced by patients 
included fever (100%), chills (50%), hypotension (40%), nausea (40%), anemia 
(40%), arthralgia/myalgia (30%), weight gain (30%), stomatitis (30%), and edema 
(30%).   The average survival of nine evaluable  patients was 198 days , with one 
patient alive and disease -free 12 years after initial vaccination64. 
Figure 2: Adverse Events by Grade 
 
    
The phase IIa  trial (IND# 8851 ) vaccinated 15 patients with stage IV melanoma. 
Each patient received a vaccination every six weeks at a dose ranging from 
250,000 -1,000,000 or more dendritomas up to six times depending on the 
availability of dendritomas a nd tumor cells.  IL -2 dose was ad ministered from 3 
MIU/m2/day on days 1, 3, and 5 after the first vaccination.  There were  two 
unrelated serious adverse events : one patient (on Coumadin) experienced gastric 
bleeding and a second experience hypoxia after IL -2 administration and required 
blood transfusions for treatment of anemia.  Erythema (33%), fever (33%), 
headache (27%), and arthralgia/myalgia (27%) were the most common adverse 
events experienced by patients.  

Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  18 Other commonly experienced adverse events included rash (20%), pain (20%), 
chills (20%), fatigue (20%), and nausea (20%).  The average survival of the ten 
deceased patients was 590 days.  Five patients remain alive.  
With 23 evaluable patients  out of the 25 enrolled  in the completed phase I/II a 
melanoma tria ls, the median overall survival  (OS)  was 12.5 months in comparison 
to the median OS of 8.5 months (4.7 to 11.5)  65 seen in historical controls  (Table 1 
and Figure 2 ).  One patient with stage IV melanoma had a partial response 12 
weeks after initial vaccination and receiv ed five vaccinations with a complete 
response  (Figure 3) .   
At interim  follow -up assessment, 13 patients had died, three  subjects had 
progressive disease, two subjects had stable disease, one subject had progressive 
disease, and four subjects had complete response  (Figure 4 ).  Of note, OS of all 
four stage IV patients with completely resected disease was 100% at 20 months.  
Although difficult to draw a dose response conclusion in a limited number of 
patients, the four subjects who had a complete response received three to six  
vaccinations and the one patient who had a partial response had five vaccinations.   
Table 1: Evaluable Patients  
        
      
 
  
 
  

Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  19 
Figure 3: Overall Survival   
 
 
 
 
 
 
 
 
Figure 4: Number of Inoculations    Figure 5: No Evidence of Disease  
 
 
 
 
 
 
 
 
Overall, data from the above trials in late -stage melanoma patients showed the 
safety of a dendritoma  vaccine itself as well as increased survival when compared 
to conventional treatments.  
The adverse events listed above were felt to be related the admini stration of IL -2 
and not the vaccine itself.  In addition, better  survival rates were seen when all 
visible tumor was removed at the time of surgery.   
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  20 A similar vaccination strateg y was also utilized in a phase I , open label, study of 
ten patients with s tage IV renal cell carcinoma  (IND# 9519) .  Each patient received 
a vaccination every six weeks at a dose ranging from 500,000 -1,000,000 or more 
dendritomas .  IL -2 dose was increased from 3 MIU/m2/day if tolerated to a 
maximum dose of 9 MIU/m2/day for five days (administered one day after first 
dendritoma vaccine but not after subsequent vaccinations).   Twelve weeks after 
initial vaccination, one patient die d, four patients had progressive disease, three  
had stable disease, and one had a partial response.  At final follow -up, nine 
patients are deceased.  The remaining patient was withdrawn due to medical 
problems requiring steroid treatment, a prohibited conc omitant medication. This 
patient is being followed for survival. The cumulative summary of adverse events 
from the clinical study showed that fever (90%), nausea (70%), vomiting (60%), 
anemia (60%) and chills (60%) were the most common AEs experienced by t he 
patients. Other commonly experienced AEs included unspecified pain (50%), 
stomatitis (40%) and weight loss (40%).  Average survival of the first six deceased 
patients in the phase I trial was 274 days with three  patients living greater than 18 
months an d one patient still alive with no evidence of disease at two years.   These 
results suggest a possible clinical benefit although  a larger , controlled trial is 
needed to draw meaningful conclusions . 
As discussed above, the concept of an autologous tumor/DC v accine has been 
made simpler with the use of the YCWP loading system , which allows the efficient 
and effective delivery of autologous tumor lysate to the patient’s DC.  In addition 
to being simpler, the TLPLDC vaccine has been shown to be more effective in  
animal models compared to the dendritoma approach although both systems 
utilize autologous tumor and DC.  We are currently utilizing the new technology of 
TLPLDC in an ongoing treatment registry  study  of multiple solid tumors  in Cayman.  
This non -IND foreign clinical trial is being conducted by GCP and meets the criteria 
of 21 CFR 312.120 .  Thus far, 1 0 patients have completed the vaccination series 
of 1x106 TLPLDC intradermally  per monthly inoculation x 4 with very limited to xicity 
(no grade >2).   Clinical activity has been documented in 60% of the wide variety of 
patients vaccinated to date (2 complete responses, 2 partial responses, and 2 with 
stable disease).  Thus far, 40% have shown progressive disease, but none of these 
received all four inoculations .  One partial responder subsequently developed 
progressive disease.  Initial clinical response in stage IV melanoma patients has 
been impressive but in small numbers.   One of three vaccinated stage IV 
melanoma patients has ac hieved a complete pathologic response (see detailed 
information in the Investigator’s Brochure).   Based on this initial safety data using 
the new technology and our prior promisi ng clinical responses with autologous 
tumor/DC vaccination in stage IV  melanom a patients , especially resected stage 
IV, we are moving forward with a phase IIb trial in the adjuvant setting.  
  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  21 3.0 OBJECTIVES  
In this  combined  study, we intend to assess the ability of the  tumor lysate, particle -
loaded, dendritic cell ( TLPLDC ) vaccine given in the adjuvant setting to prevent 
recurrences in patients with  stage III and IV (resected) melanoma .  Also, the t umor 
lysate, particle only (TLPO) vaccine is being studied in  an embedde d phase I/IIa 
trial with safety, immune response and early efficacy endpoints as described 
below.       
3.1 Primary O bjective  
For the TLPLDC phase IIb, t he primary objective is to compare DFS at 24 months 
between the vaccinated (TLPLDC and TLPO) and control  groups  analyzed as a 
proportion . 
For the TLPO phase I/IIa, the primary objective is to assess the tolerability of the 
TLPO vaccine per CTCAEv4.03.  
3.2 Secondary Objectives  
For the TLPLDC phase IIb:  
• Compare DFS and overall surv ival (OS) at 36 months  between the 
vaccinated (TLPLDC and TLPO) and control groups from time of 
randomization.   
• Compare safety between vaccinated (TLPLDC and TLPO)  and control 
groups by a ssess ing local and systemic toxicities using standard National 
Cancer Institute ( NCI) Common Terminology Criteria for Adverse Events 
(CTCAE ) v4.03. 
3.3 Exploratory  Objectives  
For both trials:  
• Evaluate  immune responses  among the vaccinat ed patients and 
compare to the control patients.  
• Correlate immunologic responses to clinical outcome.   
• Assess ongoing vaccination after recurrence for safety and tumor 
response in combination with SoC therapies to include checkpoint 
inhibitors.  
 
 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  22 4.0 STUDY DESIGN  
4.1 Description of Study  
This will be a multi -center, prospective, randomized, blinded, placebo -controlled 
phase II b trial of the autologous TLPLDC vaccine and a phase I/IIa trial of the 
TLPO vaccine (Appendi xes A and B ).  The vaccine s to be used in this study are 
investigation al and will be used under  Investigational New Drug (IND) application s 
(IND#16101  for TLPLDC  and IND#17274  for TLPO) .  The Sponsor  of these INDs 
is Elios Therapeutics, LLC . 
The target study population is melanoma patients  after complete surgical excision 
with high risk for recurrence .  High -risk patients are  defined as:  
• Stage III resected patients.  Stage IIIA, IIIB, and IIIC will be allowed; 
however, it is unlikely that many stage IIIA patients will be enrolled 
given the require ment for tumor to produce the vaccine (detailed later).   
• Stage IV resected patients.  All clinical/radiographic disease must be 
resected.   
Stage III and Stage IV (resected) melanoma patients will be identified prior to 
definitive surgery and screened for  inclusion/exclusion criteria.   
Eligible patients will be counseled and consented for tissue procurement (consent 
#1).  Enrolled patients will have their disease surgically resected  per SoC (need 
not occur at the study site) , and a portion (approx. 1 cm3 preferred but 1 mg 
minimum  of their melanoma sterilely frozen in provided freezing vials and storage 
tubes.   
This tissue will be shipped in liquid nitrogen shippers through FedEx to our central 
facility in Greenville, SC and stored frozen until  vaccine preparation.  If patients 
cannot be rendered disease -free, they will be considered screen failures for this 
study.  If melanoma is being resected from multip le locations ( i.e., primary and 
nodes or  two different me tastatic sites), then samples from  all location s would be 
preferred but is not mandatory.   
As indicated by SoC per the NCCN guidelines and determined by the treating 
team, if a patient is to receive systemic therapy (chemotherapy or IFN -α) and/or 
radiation therapy, then the vaccinations will not begin until SoC therapy is 
completed. Although, patients on adjuvant check point inhibitors (CPI) may start 
the vaccine trial after showing tolerance of the CPI after 3 doses , given that there 
may be a synergistic benefit and no added toxicity when adding the vaccine to CPI.   
Once the patient is deemed clinically disease -free, they will be consented (consent 
#2) for treatment and r andomized.   Consenting should occur as close to 
completion of SoC therapies as possible  (or after demonstrating tolerance to CPI  
after 3 doses ), but may overlap completion of systemic and/or radiation therapies 
by no more than one month .  Once consented, patients will receive a single 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  23 injection of Neupogen (G -CSF) 300 µg (or its equivalent) subcutaneously 24 -48 
hrs prior to having 70 mL of blood colle cted from the patient and sent to our central 
facility for DC isolation and preparation.  Patients who cannot  tolerate Neupogen  
(or its equivalent)  or refuse it, will have 120 mL of blood drawn and sent  to our 
central facility for DC isolation and preparat ion.  Additional blood may be drawn if 
additional vaccine doses need to be made or remade for any reason.  
Vaccines will be prepared by producing  tumor lysate ( TL) through freeze/thaw 
cycling of the autologous tumor and then loaded into pre -prepared yeast cell wall 
particles ( YCWP ).  The TL -loaded YCWP will be introduced to the DC for 
phagocytosis; thus creating the TLPLDC vaccine which will be frozen in single 
dose vials.    Each vial will contain 1 -1.5 x 106 TLPLDC a nd will be  labeled with the 
patient’s unique study number.   The TLPO will be created by taking the TL -loaded 
YCWP and capping  them with silicate . The TLPO vaccine will be frozen in single 
dose vials containing 1 x 108 TLPO and will be labeled with the patient’s unique 
study number. Vaccine production and QA testing for vaccine release and shipping 
will take approximately three  weeks.   
Based  on their randomization, either autologous TLPLDC or TLPO  (active vaccine) 
or unloaded  YCWP + autologous DC (control) will be sent back to the site in a 
blinded fashion.   The patients, referring physicians, site PIs, and site pharmacists 
will be blinded to group assignment.   Regardless of assigned group, the site will 
receive six single dos e vials to be injected intradermal monthly x 3 followed by 
boosters at 6, 12, and 18 months  (Appendix C) from initial inoculation  in the same 
lymph node draining area (preferably the anterior thigh).  Patients must begin 
vaccinations between 3 weeks and 3  month s from completion of Standard of Care 
(SoC) or patients on adjuvant check point inhibitors (CPI) may start the vaccine 
trial after showing tolerance of the CPI after 3 doses . 
Frozen tumor will be maintained for  all patients.  Patients who recur will have the 
option to participate in the open label portion of the trial. At the time of confirmed 
recurrence, the study site can request to have the patient unblinded, and the 
patient will sign the open label consent form (consent #3). In the open label stud y, 
all patients will have new vaccine doses produced from stored tumor and a new 
blood draw.    If the patient is having surgery, additional tumor tissue may be 
collected or may be required if insufficient tumor is available in the freezer.  
Once open label  consent has been signed, patients will receive a single injection 
of Neupogen (G -CSF) 300 µg (or its equivalent) subcutaneously 24 -48 hrs. prior 
to having 70 mL of blood collected from the patient and sent to our central facility 
for DC isolation and preparation.  Patients who cannot tolerate Neupogen (or its 
equivalent) or refuse it, will have 120 mL of blood drawn and sent to our ce ntral 
facility for DC isolation and preparation.  Additional blood may be drawn if 
additional vaccine doses need to be made or remade for any reason. After vaccine 
is produced and shipped to the study site, patients will begin receiving the 
inoculations on  the following schedule: 0, 1, 2 and 3 months ± 1 week followed by 
booster inoculations at 6 and 9 months ± 2 weeks from initial inoculation for a total 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  24 of six doses  (Appendix C).  These vaccinations will be occurring in the background 
and not interfere wi th any SoC therapies indicated and initiated to treat the patient’s 
recurrence per NCCN guidelines.  For the open label study, patients will be 
followed for a total of 12 months with tumor assessments by i RECIST  and RECIST  
(Appendix F) on SoC follow -up ima ging 
Control patients who do not recur will be offered active vaccine at the completion 
of the trial.   It will be their choice whether to proceed with active vaccination.  
Safety data will be collected on local and systemic toxicities , graded and reported 
per the NCI Common Terminology Criteria for Adverse Events (CTCAE)  v4.03  
(Appendix D). 
Disease -free status will be monitor ed per SoC as outlined by NCCN  for three  
years .  Suspected recurrences will be documented with biop sy and pathologic 
confirmation  when ever possible .  Time to recurrence will be based on date of 
randomization to time of confirmed recurrence.  
In addition to the initial blood collection for vaccine preparation, 50 mL  of blood  will 
be collected from all patients prior to eac h of the six inoculation s and at 24 months 
from enrollment for a total of seven  time points or a total of 350 mL of blood over 
two years.  The collected blood will be sent to our central facility for immunologic 
testing of the T -cell response.  The immunol ogic responses will be correlated with 
the clinical outcomes.   Patients will follow a similar pattern if they recur and 
participate in the open label portion of the study.  
We plan to enroll at least 180 patients ( randomized 2:1, vaccine:control ) up to  120 
patients ; after enrollment of  the 120th patient the randomization will transition to 2:1 
(TLPO  phase I/IIa :TLPLDC)  for the remaining 60 patients .  The TLPO portion of 
the study is being cond ucted as an embedded phase I /IIa trial.  With 10 -12 sites 
enrolling a 0.8 pts/site/month, we anticipate en rollment to be complete in 12 -18 
months.  With a 2 -year DFS primary endpoint  and 3 -year DFS/OS secondary 
endpoint s, the trial duration is expected to be 4-4.5 years.  Open label patients will 
be followed for a year after recurrence.  
4.2 Rationale for Study Design  
Based on our prior phase I/IIa clinical trials in stage IV melanoma, clinically 
disease -free patients real ized the greatest benefit from vaccination.  As such, 
stage III and IV (resected) patients are the target population for this adjuvant trial. 
Prevention of recurrence is the primary objective.   
Assuming a baseline recurrence rate of 60% (corresponding to a DFS of 40% ) at 
two years based on published data in this mixed group of stage III (predominantly 
IIIB and IIIC) and stage IV (resected) melanoma patients, a sample of size of 120 
will have 80% power to detect a statistical difference  in pr oportions  between 
treatment arms co ntrolling the type I err or at alpha = 0.05 (two -sided).  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  25 A blinded evaluation of the first 75 patients enrolled discovered an early recurrence 
rate of 12% prior to completion of primary vaccine series. To compensate for this 
early recurrence rate  and to pre serve the power of  the trial , enrollment will be 
extended by at least an additional 20 patients, now totaling at least 140.  After the 
randomization of the 120th patient, then randomization will transition to a 2:1 (TLPO  
phase I/IIa :TLPLDC) for an additiona l 60 patients resulting in an additional 20 
patients receiving the TLPLDC vaccine (therefore 140 as stated above) . The total 
expected enrollment after the initiation  of the TLPO phase I/IIa trial is at least 60 
patients (40 TLPO  phase I/IIa  and 20 additional TLPLDC; Appendix B) . In the 
TLPO phase I/IIa, the tolerability of the TLPO vaccine will be assessed primarily.  
Given the embedded nature of the trial and the randomization of the patients to the  
TLPO phase I/IIa vs TLPLDC, there will be an opportunity to compare the toxicity 
profiles of the two vaccines.  
In an attempt to allow all patients to benefit from receiving an autologous TLPLDC  
or TLPO vaccine  and to assess the potential for synergistic b enefit of active 
vaccination added to SoC therapies, all patients regardless of randomization will 
be offered the opportunity to participate in the open label portion of the study if they 
should recur.   These open label secondarily treated patients will be  followed for 
documentation of treatment response.  Additionally, control patients who do not 
recur can request active vaccination after they complete the trial.  
4.3 Outcome Measures  
4.3.1 Primary outcome measure s 
Disease state  will be determined by the patients’ own physicians  at the individual 
study sites during their routine follow -up screening.  This will occur for all enrolled 
patients, regardless of randomization, approximately every three  to six months for 
three years fro m randomization  with clinical exam, laboratory and radiographic 
surveillance as indicated.  This follow -up strategy is SoC for these patients  per 
NCCN guidelines .  If records are not available, patients, or their referring 
physicians, will be contacted to  discern their disease status.  Recurrences will be 
confirmed pathologically , when ever possible, per standard of care.    
For the TLPLDC phase IIb, t he primary outcome measure of the trial is DFS  at 24 
months  compared between the vaccinated (TLPLDC)  and control groups after the 
final enrolled patient completes two  years of follow -up. 
An interim analysis will be performed six months after the 120th  patient is enrolled.  
This analysis will compare median DFS bet ween vaccinated (TLPLDC)  and control 
groups.  
For the TLPO phase I/IIa, the primary outcome measure is safety as assessed by 
CTCAE v4.03 graded toxicity scale (Appendix D).  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  26 4.3.2 Secondary outcome measures  
For the TLPLDC phase IIb, the s econdary  outcome measures include  36 mo nths 
DFS and OS  and assessing local and systemic toxicities.  
DFS and OS  at 36 months will be assessed and compared between vaccinated 
(TLPLDC) and control groups .  This assessment will be conducted after the last 
enrolled  patient has been followed for three  years.  
For both studies, s tandard  local and systemic toxicities will be collected and graded 
per the NCI CTCAE v4.03 graded toxicity scale (Appendix D).   
For both the primary and the booster inoculations, patients will be monitored for  30 
minutes  after the inoculation with vital signs taken as needed. Local or systemic 
toxicities will be collected and graded by the research staff at the patient’s next 
visit. Serious AEs will be  reported as described in Section 6.0. 
4.3.3 Exploratory  outcome measures  
For both trials, i mmune  responses will be primarily documented using the 
assessment of local reactions and future CTL assays on stored blood and 
assessment of stored serum pre - and post -vaccination.  Each of these 
measurements will  be performed regardless of randomization.  Detailed 
descriptions of these assays/tests are descri bed in Section s 5.4.4, 5.4.5, and  5.4.6 .   
Phenotypic assays (dimer/tetramer) for clonal CTL expansion against common 
melanoma -associated antigens such as gp -100 and MART -1 as well as functional 
assays like ELISPOT against the same antigens will be perform ed on 
banked/stored blood.   Antibody and cytokine responses may be assessed on the 
stored serum.   Blood /serum  will be collected prior to each inoculation (0, 1, 2, 6, 
12, 18 months) and at study completion at 24 months  from randomization.  
Comparisons will  be made between the immunologic responses in the vaccinated 
(TLPLDC and TLPO) patients vs the control patients.  
In a series of exploratory analyses, the results of these immunologic measures will 
be correlated with clinical outcome in the vaccinated (TLP LDC and TLPO)  patients.  
Additional exploratory outcomes will compare clinical and immunological 
outcomes based on the dose of vaccine (TLPLDC and TLPO)  and number of 
inoculations received.  
If enrolled patients recur, they will be offered participation in the open label portion 
of the study regardless of their randomization.  All patients will have new vaccine 
produced, and they will receive inoculations at 0, 1, 2, 3, 6, and 9 mos (Appendix 
C).  They will receive the vaccinations in the background of their SoC therapies 
initiated to treat their recurrence.  These patients will be followed for safety and 
tumor response in combination with their SoC therapies and assessed per 
iRECIST  and RECIST  (Appendix F ) of their SoC follow -up scans.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  27 4.4   Safety Considerations  
In our previous trials , the safety of the autologous tumor/DC vaccines has been 
excellent.  In the completed melanoma phase I  where the autologous tumor/DC 
vaccine was given with IL -2, the most common adverse events experienced by 
patients included fever (100%), chills (50%), h ypotension (40%), nausea (40%), 
anemia (40%), arthralgia/myalgia (30%), weight gain (30%), stomatitis (30%), and 
edema (30%).   There were no SAE ’s related to the vaccine/IL -2. 
In the completed melanoma phase IIa where the IL -2 dose and frequency was 
reduce d, the most common adverse events were erythema (33%), fever (33%), 
headache (27%), and arthralgia/myalgia (27%).  Other commonly experience d 
adverse events included rash (20%), pain (20%), chills (20%), fatigue (20%), and 
nausea (20%).   
Many of these tox icities are attributable to IL -2, which will not be used in the current 
study.  We have seen minor toxicities (grade 1 and 2) transient flu -like symptoms 
in the 12 patients vaccinated without IL -2 in the treatment registry with the new 
technology, TLPLDC v accine.   We anticipate a similar favorable safety profile in 
this trial, but all local and systemic toxicities will be documented, graded by the 
NCI CTCAE  v4.03  and reported as indicated below in Section 6 .0. 
Additionally, there is a small risk associated with the protocol -dictated single dose 
of Neupogen , or its equivalent,  prior to the initial blood draw for DC isolation.  
Neupogen is a FDA -approved drug for increasing the white blood count, is 
commonly used in oncology patients, and has a well -tolerated toxicity profile.  
Thus far, in this study, we have seen no significant local reactions in any of the 
blinded patients vaccinated with the TLPLDC vaccine or placebo nor has there 
been any systemic safety signal noted by the DSMB.  However, for the TLPO 
vaccine phase I/IIa component, this is a first in human study; therefore, the safety 
of this vaccine is unknown.  As such, the primary endpoint of this embedded trial 
is safety.  Since the silicate -capped, tumor lysate -loaded YCWP are being given 
alone (not contained within autologous D C), then the vaccinated patients may form 
a different reaction to this version of the vaccine.  While the phase I/IIa TLPO trial 
is not a dose escalation trial, we will modify the dose based on local and systemic 
toxicities.   
Dose Reductions of Vaccine.  For patients experiencing robust local reactions 
(>100mm  of erythema/induration and/or threatened skin disruption),  or >/= grade 
3 local and/or systemic reactions , or >/=  grade 2 hypersensitivity reactions, the 
dose of the vaccine will be reduced  by 50% fo r subsequent inoculations.  If 
reactions /toxicities  recur with subsequent inoculations , the vaccine dose will 
continue to be reduced serially by 50%.  If dose reduction does not control toxicities 
or they worsen despite reductions, then all further inoculations will be halted.   
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  28 4.5   Compliance with Laws and Regulations  
This study will be conducted in accordance with current FDA regulations and 
Good Clinical Practices (G CPs), and local ethical and legal requirements.  
5.0   MATERIALS AND METHODS  
5.1 Subjects  
Patients over the age of 18 years with a diagnosis of stage III or IV melanoma 
capable of being rendered clinically disease -free after surgery will be targeted.  
Patients will be recruited from medical and surgical oncology and/or 
hematology/oncology clinics at the individual study sites.   All patients will be 
properly counseled and consented.  
5.1.1  Subject selection  
Potentially eligible patient s, specifically patients with clinical stage III and stage IV 
resectable melanoma will be identified by staff in the medical and surgical and/or 
the hematology/oncology clinics at the individual study sites.   
A research nurse and/or study coordinator will  approach these patients about 
being in the trial and will introduce the trial to the prospective volunteer.  If the 
volunteer is interested and appears eligible, the nurse will arrange to counsel the 
patient.  The nurse will thoroughly screen the patient for inclusion and exclusion 
eligibility criteria.  If the patient remains interested and eligible, informed consent 
will be obtained  for tissue procurement (consent #1).  
Written informed consent will be obtained from all study participants.  Prospective 
participants will be provided with a copy of the consent form #1 to read.   
The research nurse coordinator and/or study coordinator, or Principal Investigator 
(PI), will explain the study and review the consent form with the patient.  Subjects 
will be given ample time to ask and have all questions answered prior to signing 
the consent form.   
After SoC surgery  (which need not occur at the study site) , if the patient is rendered 
clinically disease -free, sufficient  tumor is a vailable for vaccine production  (1 cm3 
preferred, 1mg minimum) , and all other eligibility criteria are met, then the patient 
can be counseled and consented for randomization and treatment (consent #2).  
This consenting should occur as close to completion of indicated SoC thera pies as 
possible (or after demonstrating tolerance to CPI  after 3 doses ), but may overlap 
completion of systemic and/or radiation  therapy by no more than one month .  Once 
the second written informed consent is obtained, the patient will receive a single 
injection of Neupogen (G -CSF) 300 µg (or its equivalent)  subcutaneously 24 -48 
hours prior to having 70 mL of blood collected from the patient and sent to our 
central facility for DC is olation and preparation.  Patients who cannot  tolerate 
Neupogen  (or its equivalent)  or refuse it, will have 120 mL of blood drawn and sent . 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  29 Additional blood may be drawn if a dditional vaccine doses need to be made or 
remade for any reason.   The full course (six doses) of the TLPLDC or TLPO  
vaccine vs placebo vaccine (empty YCWP + DC) will be p roduced at one time after 
randomization.   The production and QA testing for vaccine release will take 
approximately three  weeks.  Vaccination cannot begin u ntil after all SoC therapies 
are completed, but the inoculation series must begin within 3 weeks and 3 months 
from completion of SoC therapies.    
Tumor will be maintained on all patients to include the control patients so that 
active vaccine can be reproduced if necessary , in the case of the vaccine patients 
or be made  for the control patients  in the case of recurrence or upon request at the 
end of the primary  endpoint.      
5.1.2  Inclusion criteria  
Patients will be included in the study based on the following criteria:  
• 18 years or older  
• Eastern Cooperative Oncology Group (ECOG) performance status 0,1  
(Appendix E) 
• AJCC stage I II or IV completely resectable melanoma  identified before 
surgery  
• Approximately 1 cm3 preferred but 1 mg minimum  of accessible and 
dispensable  tumor that will not in terfere with pathologic staging  
• Clinically disease -free after surgery  
• Completing  SoC adjuvant therapy per NCCN guidelines to include 
chemotherapy, radiation therapy, and/or biologic therapy as clinically 
indicated .  (Consent  #2 should be signed as close to completion of 
SoC as possible but may overlap completion by up to one month .)  
ONLY  for patients on CPI therapy: The patient has completed all other 
SoC therapy per NCCN and has demonstrated tolerance of treatment 
after 3 doses of CPI therapy  without serious adverse events and 
remains clinically disease -free. (Consent #2 should be signed  after the 
3rd dose  of CPI therapy.)  
• Vaccinations initiated between 3 weeks and 3 months from completion 
of SoC multi -modality cancer care  or after tolerance to CPI therapy has 
been determined . 
• Adequate organ function as determined by the following laboratory 
values:  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  30 • ANC ≥ 1,000/μL  
• Platelets ≥ 75,000/μL  
• Hgb ≥ 9 g/dL  
• Creatinin e ≤ 1.5 x upper limit of normal (ULN) or Creatinine 
clearance ≥ 50%  of lower limit of normal (LLN)  
• Total bilirubin ≤ 1.5 ULN  
• ALT and AST ≤ 1.5 ULN  
• For women of child -bearing potential, agreement to use adequate birth 
control (abstinence, hysterectomy, bilateral oophorectomy, bilateral 
tubal ligation, oral contraception, IUD, or use of condoms or 
diaphragms)  
• Signed informed consent  
5.1.3 Exclusion criteria  
Patients will be excluded from the study based on the following criteria:  
• Evidence of residual disease after surgery and SoC adjuvant 
therapies  
• Insufficient tumor available to produce vaccine  
• ECOG >2 performance status  (Appendix E) 
• Immune deficiency disease or known history of HIV, HBV, HCV  
• Receiving immunosuppressive therapy including chronic steroids, 
methotrexate, or other known immunosuppressive agents  
• Pregnancy (assessed by urine HCG)  
• Breast feeding  
• Active pulmonary disease requ iring medication to include multiple 
inhalers  (>2 inhalers and one containing steroids)  
• Involved in other experimental protocols (except with permission of 
the other study PI)  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  31 5.2 Method of Treatment Assignment  
If volunteers meet all inclusion criteria and  none of the exclusion criteria and agree 
to participate, they will continue in the study.  After tissue procurement, if adequate 
tumor is available for vaccine production  (1 cm3 preferred, 1 mg minimum)  and 
patients are rendered clinically disease -free, then they will be consented and 
randomized for treatment assignment.   
Patients will be randomly assigned by the CRO  using a computer -generated 
randomization table to receive the autologous TLPLDC vaccine or placebo (empty 
YCWP + autologous D C).  Randomization between the two tr eatment groups will 
occur in a 2 :1 allocation ratio using an institutional balancing algorithm.  After the 
120th patient is randomized, the TLPO phase I/IIa trial will commence with a 2:1 
(TLP O phase I/IIa:TLPLDC ) rando mization for an additional 60 patients  (refer to 
Appendix B). This randomization will use the same computer -generated 
institutional balancing algorithm and the patients will be randomly assign ed by the 
CRO .  Patients , treating physicians, and site PIs  will be blinded as to the treatment 
assignment.  Active vaccine will be made available to those patients assigned to 
the control group at time of recurrence  or after the y have completed the trial , 
including all follow -ups and primary and secondary endpoin ts, if they have not 
recurred and wish to receive the active vaccine.   
5.3 Study Treatment  
5.3.1 Vaccine production  
Vaccines will be produced by Orbis Health Solutions (Greenville, SC).  Tumor 
lysate from the patient ’s tumor is loaded into YCWP  which are phagocytized by the 
patient ’s dendritic cells in vitro to generate TLPLDC. The TLPO vaccine is 
produce d from the patient’s tumor lysate loaded into YCWP and capped  with 
silicate .   
The final vaccine contains 1 -1.5 x106 TLPLDC or 1.0 x 108 TLPO per dose and will 
be provided in frozen single dose vials in 250 µl of freezing media  for TLPLDC and 
saline for TLPO .  The final vaccine is prepared for injection by thawing the single 
dose vial and diluting the vaccine ( TLPLDC  or TLPO)  by adding 500 µl of sterile 
saline for injection.   
For the open label portion of the study, new vaccine will be made for all patients 
from frozen tumor and a new blood draw.  
5.3.1.1  Preparation of dendritic cells 
Dendritic cells will be generated from the patient's peripheral blood monocytes  
(PBMC)  obtained from the post-Neupogen  (or its equivalent)  70 mL blood draw or 
from 120 mL of blood drawn if Neupogen  (or its equivalent)  not used  after consent  
#2.  The PBMC s are initially diluted and placed in a plastic culture flask for 2 h ours.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  32 Non-adherent cells are washed away and collected.  These cells are rich in 
lymphocytes and will be frozen for future assays.   
The adherent cells will be incubated at 37°C in 5% CO 2 for two days in serum -free 
cell culture medium with the appropriate cytokines added to generate immature 
monocyte -derived dendritic cells . 
5.3.1.2  Tumor tissue preparation  
A minimum of 1 mg  sample of viable tumor tissue is required to be collected at the 
time of primary surgery.  The specimens will be collected and placed in sterile 
freezing vials that will be provided and then shipped in speci alized FedEx shippers 
designed to keep the specimens frozen (also provided).  The cells of the tumor 
tissue will be lysed by multiple freeze/thaw cycles in lysis buffer to produce tumor 
lysate.  
5.3.1.3  YCWP preparation  
YCWP  are prepared by NaOH digestion of all non -cell wall material from 
Fleishman ’s Bakers ’ yeast, Saccharomyces  cerevisiae, followed by thorough 
aqueous, ethanol , and acetone washings.  
5.3.1.4  Loading of YCWP with tumor lysate  
TLPLDC are generated by incubatin g tumor lysate loaded YCWP  in the presence 
of dendritic cells at a specific time during day 2 of the DC 
isolation/ incubation /maturation process .  The timing is essential in that the 
immature DC are given the YCWP  at their most phagocytic phase.   For control 
patients, empty YCWP will be incubated in the presence of DC at the same point 
on day 2 of the DC incubation.  
5.3.1.5  Capping of TL-Loaded of YCWP with Silicate  
TLPO vaccine is generated by capping tumor lysate -loaded YCWP  with silicate . 
The fully loaded, dried YCWP are added to a solution of ammonium hydroxide, 
tetraethylorthosilicate and 100% ethanol and shaken vigorously for 15 minutes in 
order to “cap” the particles with a silicate coating.  Following “capping,” the loaded 
and “capped” YCW P are washed multiple times in PBS with sonication to remove 
all “capping” reagents.  After washing, the suspension of “capped” tumor lysate -
loaded YCWP (TLPO) is aliquoted into individual doses each containing 1x108 
TLPO  in 250 uL of sterile saline and fr ozen.  
5.3.2 Storage  
Six doses of 1 -1.5 x 106 autologous TLPLDC  or 1.0 x 108 TLPO  will be 
cryopreserved in patient -specific labeled single dose vials and maintained at the 
central production facility at -80◦C until shipped. Once approved for release, the 
entire vaccine series (all six doses) will be shipped to the site frozen in specialized 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  33 LN shippers.  The patient -specific dose series will be stored at the site at  least -
70°C in the research pharmacy  until serially thawed for use . Any temperature 
excursion for more than 30 minutes at -55◦C or warmer needs to be reported. 
Outside of preparation for patient injection, the vaccine may not, at any time , be 
allowed to thaw. The isolated 250ul vial will thaw in less than one minute at room 
temperature.    
5.3.3 Inoculation series – administration  
Patient s will receive six  intradermal inoculations on the anterior or medial side of 
the same thigh  or arm . The general area of inoculation will be at a location midway 
between the inguinal ligament and the knee.  
Before injection, this cellular vaccine will either  be thawed slowly  in a 370 C water 
bath or the vaccine vial can be held in a gloved hand until thawed if water bath is 
not available . The vial should not be left lying out to thaw at ambient temperature. 
The 250 µl of thawed TLPLDC  or TLPO  will be diluted with 500 µl of st erile saline 
for injection.  The final 750 µl volume will be d rawn up into a 1 mL syringe  and 
should be injected within 4 hours .  The entire contents of the s yringe will be injected 
intradermally in two  approximately equal inoculums at two different sites 5 cm from 
each other  on the anterior or medial thigh or arm . Inoculations will be administered 
in the same lymph node d raining area (same arm or leg)  (see also Appendix C).   
The research nurse coordinator will administer the inoculations steril ely in the clinic  
facility located at each study site. For female patients with childbearing potential, 
a urine pregnancy test will be performed before each inoculation. If this test is 
positive at any time, the patient will be discontinued from the study.  
Initial inoculat ions will be performed at 0, 1, and 2 months  ± 1 week  followed by 
booster inoculations at 6, 12, a nd 18 months  ± 2 weeks  from initial inoculation  for 
a total of six doses.   
For the open label portion of the study, inoculations will be performed at 0, 1, 2,  
and 3 months, ± 1 week and at 6 and 9 months, ± 2 weeks for a total of six doses.  
5.3.4  Dose reduction for TLPO  
Patients experiencing robust local reactions or unacceptable toxicities (see section 
4.4 for definitions) will have their TLPO dose reduced by 50%.  This will be 
accomplished by doubling the sterile saline diluent and maintaining the same 
inoculation volum e.  
5.4 Study Assessments  
Signed, IRB  approved informed consent must be obtained from patients prior to 
any pretreatment assessments.   
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  34 5.4.1 Pretreatment assessments  
This trial requires two consents: one for tissue procurement and one for 
randomization/treatment.  The second consent will be signed once a patient has 
been rendered clinically disease -free after surgery , adequate tumor tissue has been 
acquired for vaccine production , and all eligibility criteria are met .  Consent #2 will 
be si gned as close to completion of SoC therapies as possible but may overlap 
completion of systemic and/or radiation therapy by up to a month.  For those patients 
on CPI therapy, they must have completed 3 doses  of therapy and demonstrated 
clinical tolerance be fore continuing with consent #2.   Initiation of vaccination cannot 
begin until SoC therapy has been completed  (and/or demonstration of 3 doses  of 
CPI tolerance, as applicable) , but must begin 3 weeks to 3 months from completion 
of SoC  (or after 3 doses  of CPI therapy demonstrating tolerance) . 
All patients must have a CBC  with differential , CMP , and LDH  within two months of 
trial initiation and, for female patients, a urine pregnancy test (upon consent to 
study), for screening and immed iately prior to any vaccine inoculations.   If the 
pregnancy test is positive the patient will be excluded from the study .  Women who 
have had a hysterectomy, bilateral ooph orectomy, tubal ligation, documented 
absence of menses for two years, or FSH hormona l laboratory results that verify 
menopause, will not be required to have pregnancy testing.   
For patients who have a complete metastatic evaluation (CBC, LFTs, CXR, chest 
and abdomen CT, bone scan, and PET scan) available, all studies will be screened 
but these studies are not required for enrollment.  Disease -free status will be assured 
by the patients’ primary treating/referring physician.  Overall health screen will be 
assessed utilizing the ECOG performance status gradi ng system (Appendix E). 
All patie nts regardless of randomization will  be assessed for baseline  and post -
vaccination  immunologic responses.  Blood samples will be obtained prior to each 
inoculation (0, 1, 2, 6, 12, 18 months) and at study completion at 24 months from 
randomization.  The protocol schedule of events is listed in Appendix G.   
Specimen handling, processing, and assays are describe d in Sections 5.4.4 , 5.4.5,  
and 5 .4.6. 
5.4.2 Assessments during treatment  
Any laboratory evaluations or imaging studies ordered by the treating oncologist 
as part of standard practice will be reviewed by the research nurses or study 
coordinators and any abnormal results will be reviewed by the study 
investigators.  
Research nurses or study coordinators will assess the patients prior to and during 
a 30 minute  observation after vaccine inoculation, and will assess the patient on  
an “as n eeded” basis.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  35 For both the primary inoculation s and booster series, the patients will be monitored 
for 30 minutes after  the inoculation with vital  signs taken as needed.    Local or 
systemic toxicities will be collected and graded by the research staff at the patient’s 
next visit.  The NCI CTCAE v4.0 3 graded toxicity scale (Appendix C) will be utilized 
to assess local and systemic toxicity.   
Blood samples will be obtained fr om all patient s, regardless of randomization,  to 
determine induction of  anticancer immune responses as described in Sections 
5.4.4 , 5.4.5,  and 5 .4.6. 
5.4.3 Follow -up assessments  
The clinical endpoint of recurrence will be determined by the patients’ own 
physicians at the individual study sites  during routine follow -up.  This will include 
history and physical examination every 3 -6 months for all patients .  Additional 
laboratory and radiographic surveillance  will be performed  as indicated  and 
directed by the patients treating physicians .  The determination of recurrence will 
be per standard practice  by the treating physicians and communicated to the study 
investigators on a rout ine basis.  Documentation of any  recurrence will be 
obtained.  Whenever possible, pathologic confirmation of recurrence will be 
obtained.   
However, a patient will also be considered to have a recurrence if highly suggested 
on radiographic evaluat ion and oncologic  treatment for the recurrence is initiated 
by the treating physician.  Documentation of the latter will be obtained.    For the 
purposes of this trial, DFS will be cal culated from the date of randomization until 
date of last follow -up or recurrence .   If records are not available, patients, or their 
referring physicians, will be contacted to discern their disease status and every 
effort will be made to obtain documentation.   
Once a patient recurs, they will be offered the opportunity to participate in the open 
label portion of the study.  The patients will be vaccinated at 0, 1, 2, 3, 6, and 9 
months.  Assessments during inoculations and blood draws will be the same as 
above.  These patients will be treated per SoC for thei r recurrence.  The 
vaccinations will be performed in the background and will not interfere with SoC 
treatments.  Additio nal laboratory and radiographic surveillance will be performed 
as indicated and directed by the patients treating physicians and per sta ndard of 
care.  The determination of tumor response will be assessed on these SoC scans 
per RECIST and i RECIST  (Guidelines for the Evaluation of Immune Therapy 
Activity in Solid Tumors) (Appendix  F).  These results will be communicated by the 
primary study  investigators on a routine basis.   
All enrolled patients, regardless of randomization, will be followed for clinical 
recurrence  and overall survival  for a minimum of three  years  from randomization.   
The open label patients will be followe d for 12 months.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  36 5.4.4  Blood collection and processing  
Multiple blood draws will be required for this trial. All blood tubes will be labeled 
only with the patients’ unique study number.  Approximately 50 mL will be collected 
for immunologic assessment s prior to each inoculation (0, 1, 2, 6, 12, and 18 
months) and at 24 months from  randomization.   Thus , a total of approximately 350 
mL of blood will be drawn over the  two-year course of the study.  De -identified 
patient blood samples showing only the unique study ID number will be sent from 
study sites via overnight delivery to our central lab facility in Greenville, SC where 
they will be stored until used for immunologic assays (Section 5.4 .6).  At no point 
will laboratory  personnel have access to patient identifiers.  Blood will b e frozen 
and stored under unique study numbers for up to five years for additional 
immunologic studies related to this protocol (for example, to repeat assays or 
perform new immunologic assays that do not exist at present but may become 
available) as neede d and then destroyed.  No genetic testing will be performed on 
this material.  Study participants will not be contacted in the future for additional 
use of these stored blood specimens.  If study participants want their blood 
specimens removed from storage  and destroyed, they may do so by contacting 
the PI or research nurse at any time.  Additionally, any stored blood may also be 
utilized to assess new generations of vaccines. A similar schedule will be followed 
for the open label portion of the study.      
The 50 mL of blood will be collected as 10 mL  into a BD Vacu tainer Rapid Serum 
tube (BD, Franklin Lakes, NJ) which contain a clot activator and silicone coated 
interior.  After receipt and centrifugation, serum will be collected, aliquoted in vials  
and frozen.  The remaining 40 mL will be  collected into four BD Vacutainer Heparin 
tubes (green tops ), which  contain an anticoagulant (sodium heparin ).  Once 
received, the heparinized blood will b e pooled, diluted, and added to FICOLL 
HYPAQUE density gradient fluid containing tubes to allow for the separation of 
PBMC from the red blood cells by a single step centrifugation process.  The PBMC 
fraction will be collected , aliquote d, and frozen for fut ure use in immunologic 
assays.  
5.4.5  Phenotypic assay (for example, d extramer  assay) for melanoma -specific 
antigens   
Thawed and cultured  PBMC will be stained with aqua live/dead stain (Invitrogen) 
and the following antibodies:  CD8 APC -H7 (BD Biosciences) , CD3 PE Cy7 (BD 
Biosciences), gp100 -APC-conjugated dextramer (Immudex), and the following 
pacific blue conjugated lineage antibodies:  CD14 (BD Biosciences), CD16 (BD 
Biosciences), and CD19 (Biolegend ).  Cells will be analyzed on a Canto flow 
cytometer (BD Biosciences).   
The frequency of gp100 -specific CD8+ T-cells will be determined as the percentage 
of cells that are alive, lineage -, CD3+ CD8+ and gp100 -dextramer+.   This assay 
may be performed for o ther known CD8+ epitopes from known melanoma -specific 
antigens.   
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  37 5.4.6   Functional assay (for example, ELISPOT assay) for melanoma -specific 
antigens  
Thawed and isolated PBMC are cultured/stimulated overnight in complete medium 
(RPMI + 5 %FCS + PSG) supplem ented with IL -7 (20 ng/mL) with the individual 
peptides at 25 μg/mL (gp100, MART -1, etc.) or PMA + Ionomycin in flat -bottom 
anti-human IFN -γ ELISPOT plates (BD PharMingen) at 5 x 105 cells/well/200 μL  in 
duplicate wells.  The plate is incubated at 37ºC overnight after which the wells will 
be washed and incubated with the biotinylated -anti-IFN-γ mAb for two hours.  The 
wells will be washed again and incubated with streptavidin -conjugated HRP for 
one hou r.  After a final wash the AEC -substrate solution will be added to the wells 
and allowed to develop for approximately 5 -10 minutes at which time the wells will 
be washed with deionized water to stop the reaction.  The number of spots present 
in each well w ill be enumerated using the CTL ELISPOT analyzer (CTL Analyzers 
LLC, Cleveland, OH).  
5.5 Discontinuation of P rotocol -Specific Therapy  
Protocol -specific therapy may be discontinued for any of the following reasons:  
• Progressive disease  
• Unacceptable toxicity as described in the protocol :  
o Please refer to Section 4.4 (Safety Considerations ).  Adverse 
events that do not respond to clinical management of the reaction 
will result in discontinuation from the study.  
o Please refer to Section 5.6 (Subject Discontinuation) for a list of 
severe adverse reactions warranting discontinuation from the study.  
• Patient election to discontinue therapy (for any reason)  
• Physician’s judgment  
5.6 Subject D iscontinuation  
Those patients who display significant reactions ( e.g., anaphylactic reaction 
immediately after vaccine administration) or serious toxicities will be discontinued 
from the study as discussed below and as determined by the PI  and/or Sponsor .  
They will be followed by the study invest igator until resolution of the adverse event.  
Inoculations will be immediately halted if any serious adverse reactions occur to 
include: death, life -threatening adverse drug experience ( e.g.,, severe 
anaphylactic reaction immediately after vaccine administ ration), inpatient 
hospitalization or prolongation of existing hospitalization, a persistent or significant 
disability/incapacity, a congenital anomaly/birth defect, or other important medical 
events that may not result in death, be life -threatening, or re quire hospitalization 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  38 but which, when based upon appropriate judgment of the PI, be determined to 
jeopardize the patient or require medical or surgical intervention to prevent an 
outcome listed above.  Any death or grade 4 adverse drug experience found to be 
directly related to the experimental vaccine will result in suspension of patient 
enrollment to the study.  
Patients may withdraw from the study at any time and for any reason.  A patient 
may be asked to withdraw from the study by the PI if they are not compliant with 
the timing of the inoculation series, observation period, or return visits to monitor 
for study -associated toxicities.   
Additionally, if the PI determines that it is no longer safe for a patient to continue  
in the trial for any reason, he/ she may be withdrawn.   
Because it is not known whether these inoculations might harm an unborn child, 
patients who are pregnant, plan on becoming pregnant, or who are breast -feeding 
will not be enrolled into the study.  Women of childbearing potential  will take a urine 
pregnancy  test before starting this study and prior to each inoculation; a positive 
test result will terminate the patient’s participation in the study.  Patients will be 
counseled to avoid becoming pregnant while participating in this study, and that in 
order to p revent pregnancy they should either have no sexual relations or use a 
reliable type of birth control.  They will be counseled that with the exception of 
hysterectomy, bilateral ooph orectomy, or tubal ligation, birth control methods are 
not totally effectiv e in preventing pregnancy, and that the only ways to completely 
avoid the risk of the vaccine or immunoadjuvant alone to an unborn baby are (1) 
avoid becoming pregnant, or (2) do not receive these inoculations.  Patients will 
be counseled to avoid becoming  pregnant for at least six months after receiving 
the inoculations,  as pregnancy within this time after inoculation administration may 
be a risk to an unborn baby.    
If a patient is discontinued from the study for an adverse event or pregnancy, 
they will c ontinue to be followed for resolution of adverse event and clinical 
recurrences unless the patient withdraws consent for further study evaluation.  
The reason for any premature discontinuation of a patient from the study will be 
recorded on the appropriate  Case Report Form .  
5.7 Study Discontinuation  
The IND sponsor, the Data Safety Monitoring Board, and the overall study Principal 
Investigator have the right to suspend or terminate this study entirely or at a 
specific site at any time , and for any reason .  Reasons for suspending or 
terminating the study may include , but are not limited to,  the following:  
• The incidence or severity of AEs in this or other studies indicates a 
potential health hazard to subjects  
• Subject enrollment is unsatisfactory  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  39 • Data recor ding are inaccurate or incomplete  
• Study protocol not followed  
5.8 Data Collection  
Basic demographic, pathologic, and relevant clinical information will be gathered 
on each patient and entered into an Electronic Data Capture (EDC) database.  The 
URL for the  EDC system is  https://cancerinsight.eclinicalhosting.com/OpenClinica . 
The EDC system is accessible from any major web browser.  User name and 
password will be generated by the Data Man ager of Cancer Insight , LLC  and sent 
via email to appropriate site personnel prior to enrolling the ir first patient. Clinical 
nurses at the site will be provided with Source Document Flow Sheets to capture 
data at enrollment and for each study visit.  Alth ough some data fields on the Flow 
Sheets will not be entered into EDC, they must be captured on the Flow Sheets 
for monitoring purposes.  
All data must be submitted within 72 hours of the data collection visit.  Data entry 
will begin with the patient’s randomization with enrollment date to be date of signed 
informed consent.  
Edit checks will fire in real time as data is being entered in the  EDC system to 
ensure quality data is provided.  In addition to edit checks, queries will be 
generated as Discrepancy Notes from the Data Manager and Monitors.  Sites will 
have ten business days to update a query.  It is the responsibility of the coordinat or 
at each site to ensure that data has been submitted.  Cancer Insight personnel or 
the Sponsor’s representative will perform an audit of the site -specific Flow Sheets 
and will match them against source documents to ensure the quality of data 
coming to the Data Manager in the EDC per the internal monitoring plan.  
The database, hosted by OpenClinica, resides in a SAS 70 Type II data center and 
meets ISO 17799 standards for information security. The EDC system is HIPAA 
and 21 CFR Part 11 complia nt with rob ust audit logs, controlled user access , and 
electronic signature/password management.  In addition to the site user, the Data 
Manager, the Monitors, the study PI and Sponsor/Sponsor representative have 
access to the database.  Each user is assigned a role, which  grants limited ac cess 
and functionalities depende nt upon that specific role.  
5.9 Statistical Methods  
5.9.1  Rationale for study design  
Based on our prior phase I/IIa clinical trials in stage IV melanoma, the resected 
stage IV patients enjoyed the g reatest benefit from vaccination.  As such, stage III 
and IV (resected) patients are the target population for this adjuvant trial. 
Prevention of recurrence is the primary objective.   
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  40 5.9.2 Sample size determination  
Assuming a baseline recurrence rate of 60% (corresponding to a DFS of 40%) at 
two years based on published data in this mixed group of stage III (predominantly 
IIIB and IIIC) and stage IV (resected) melanoma patients, a sample of size of 120 
will h ave 8 0% power to detect a statistical difference between treatment 
proportions  controlling the type I error at alpha  = 0.05 (two -sided).  
A blinded evaluation of the first 75 patients enrolled discovered an early recurrence 
rate of 12% prior to completion of pri mary vaccine series. To compensate for this 
early recurrence rate and preserve the power of the trial, the enrollment will be 
extended by at least an additional 20 patients, now totaling at least 140.  
After randomization of the 120th patient, the randomiza tion will transition to 2:1 
(TLPO  phase I/IIa :TLPLDC) for an additional 60 patients .  The TLPO vaccine group  
(n=40)  will be assessed primarily for tolerability of the TLPO vaccine based on 
CTCAE v4.03 graded local and systemic toxicities.  Given that the p atients will be 
randomized between the TLPO phase I/IIa and TLPLDC, there will be an 
opportunity to directly compare the toxicity profile of these two vaccines.  
Also, the 20 additional TLPLDC vaccine patients will be assessed with the original 
120 randomized patients to account for the 140 patients mentioned above 
(Appendix B).  
5.9.3 Data analysis  
For the TLPLDC phase IIb, t he intention -to-treat (ITT) population will include all 
subjects who were randomly assigned.  ITT analysis will be performed wi th each 
randomized patient evaluated in the treatment arm to which they are randomized 
regardless of actual treatment received.  The per -protocol (PP) population is a 
subset of the ITT population.  
Subjects may be excluded from the PP population for the fol lowing reasons and 
others as determined prior to database lock:  violations of eligibilit y criteria, 
development of second  malignancies, early recurrences occurring prior to 
completion of the first four inoculations , receiving alternative disease -directed 
therapy without evidence of recurrence, or major deviation from prescribed 
vaccination schedule (to include boosters).  
5.9.3.1 Study patient characteristics  
Demographic characteristics of all patients in the ITT and PP populations will be 
summarized includ ing age, race, disease histology,  tumor location,  tumor depth , 
ulceration, number of mitoses , nodal status  (number and micro - vs macro -
metastasis) , AJCC clinical stage, location  and number of distant metastases (if 
present), surgery extent, and other disease -directed therapies to include 
chemotherapy, radiation therapy, and biologic therapy.  Continuous variables will 
be summarized using the number of patients, mean, standard dev iation, median, 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  41 minimum, and maximum; and categorical variables will be summarized using the 
frequency count and the percentage of patients in each category.  Differences 
between treatment groups will be determined using a chi -square test for 
categorical v ariables and a t -test for continuous variables.  
5.9.3.2 Primary efficacy analysis  
For the TLPLDC phase IIb, the primary efficacy endpoint of the trial is 24 month 
DFS when analyzed as a proportion using Pearson chi -square test . The primary 
efficacy analysi s will be performed on the ITT and the PP population as equally 
important analyses given the high early recurrence rate.  
The primary efficacy analysis will also be conducted by site for the ITT and PP 
populations in order to explore the possibility of a tr eatment by investigative site 
interaction.  Investigative sites that indiv idually represent fewer than five  subjects 
will be combined for this exploratory analysis; geographic region will be substituted 
if the average number of subjects per site is fewer t han ten.  
The primary analysis will be conducted once the 120th  patient enrolled completes 
24 months of follow -up.   
An interim analysis of DFS and compared between treatment groups will be 
performed 6 months after the 120th  patient is enrolled .  No early stopping rule is 
included.  
5.9.3.3 Secondary efficacy analysis  
For the TLPLDC phase IIb, DFS and overall  survival (OS) will be compared 
between the vaccinated (TLPLDC and TLPO)  and control groups at 36 months  
from the 120th patient enrolled .   Both DFS and OS will be measured from time of 
randomization to date of recurrence and death, respectively.   DFS and OS will be 
determined using the Kaplan -Meier method and differences between treatment 
groups will be assessed using the log -rank test.   
In addition, Cox proportional hazards regression models will be fit to determine the 
association  between  DFS and OS and treatment group. The secondary  efficacy 
analysis will be performed on the ITT and the PP population as equally important  
analyses given the high early recurrence rate . 
Due to changes in standard of practice, specifically the FDA app roval of checkpoint 
inhibitors (CPI) in the adjuvant setting, the protocol was modified to allow for the 
inclusion of patients who had demonstrated initial tolerability to CPI.  These 
patients were randomized and received concurrent CPI + either TLPLDC or 
placebo.  Therefore, as a part of the overall secondary efficacy analysis, an 
additional analysis will specifically assess DFS and OS in this subgroup of patients 
who received concurrent therapy.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  42 During the course of the trial, it has been noted that the p roduction method of the 
TLPLDC vaccine may impact clinical outcome.  As such, as a part of the overall 
secondary efficacy analysis, an analysis will be performed for DFS and OS 
comparing patients who received TLPLDC produced from 120 mL of blood vs 
TLPLDC produced after G -CSF.  Additionally, these groups will be compared to 
the placebo group in three arm analyses as well as exploratory two arm analyses 
by grouping like arms.  
5.9.3.4  Safety analysis  
For both trials, t he incidence of treatment -emergent AEs, SAEs, severe AEs, AEs 
related to study drug , (defined as not, unlikely, possibly, probably, or definitely 
related to study drug), and AEs which lead to study discontinuation will be 
summarized by treatment group.  Diff erences between treatment groups will be 
determined using Fisher’s exact tests.  
Time to AE onset will be estimated using the Kaplan -Meier method and treatment 
differences will be determined using the log -rank test. In addition, duration of any 
AE with >10 % incidence, total number of AEs, SAEs, and related AEs will be 
summarized and treatment group differences assessed using a t -test or Wilcoxon 
rank sum test, depending on the distribution of the data.  
5.9.3.5  Immunologic analysis  
For both trials, i mmunolo gic responses  will be determined  using  phenotypic and 
functional assays ( ex vivo ).  
Expression percentages will be compared using a chi -square test while continuous 
outcomes will be compared using a paired t -test (within treatment group) and a 
two-sample t -test (between treatment groups).  For the ex vivo  response evaluated 
by the phenoty pic and fu nctional assays , the number of peptide -specific CTL will 
be determined at multiple time points (see Section s 5.4.4, 5.4.5, and 5.4.6 ) during 
the trial.  
Changes from pre -vaccination levels to each time point will be comp ared,  and 
differences with in treatment group s will be evaluated using a paired t -test while 
between treatment group differences will be ev aluated using two -sample t -tests.  
In a series of exploratory analyses, the different immunologic response indicators 
(in vivo  and ex vivo ) at di fferent time points will be correlated with clinical outcome 
in order to assess for any predictors of outcome. Additional exploratory outcomes 
will compare clinical and immunological outcomes based on the dose of vaccine 
(TLPLDC and TLPO)  and number of ino culations received.  
5.9.3.6  Open Label Study  
At the time of recurrence, all patients will be offered the opportunity to participate 
in the open label portion of the study regardless of their randomization.  All patients 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  43 will have new vaccine produced, and they will receive inoculations at 0, 1, 2, 3,  6, 
and 9 mo nths.  They will receive the vaccinations in the background of their SoC 
therapies initiated to treat their recurrence.  These patients will be followed for 
safety and tumor response in combination with their SoC therapies and assessed 
per iREC IST and RECIST of their SoC follow -up scans.  
5.9.4 Withdrawal  
Subjects may withdraw or be discontinued from the study as discussed in Section 
5.6.  Subjects who do withdraw or are discontinued will be included in the efficacy 
analyses unless a subject with draws consent to participate.  In the instance of a 
subject withdrawing consent, any data collected will be excluded from analysis.  
5.9.5 Missing data 
Every reasonable attempt will be made to recover any missing data.  If any data 
remains missing that data point will be excluded from analysis for that patient.  A 
sensitivity analysis using the tipping point approach is the imputation strategy for 
missing  data as described in the SAP, Section 4.7.  
6.0 ADVERSE EVENTS   
Reporting of adverse events  (AEs)  will be performed in accordance with the Data 
Safety Monitoring Plan (DSM P) (Appendix H), this protocol , and federal 
regulations . 
6.1 Adverse Event and Reporting Definitions  
With the occurrence of an AE, the first concer n will be for the safety of the subject. 
An adverse event (AE) is any untoward medical occurrence in a subject 
participating in an investigational study or protocol regardless of causality 
assessment.  
An adverse event can be an unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, syndr ome, or disease associated with or 
occurring during the use of an investigational product whether or not considered 
related to the investigational product.  
Serious Determination:  
Serious adverse events (SAE s) are AEs occurring at any dose which meet one 
or more o f the following serious criteria : 
• Results in death (i.e., the AE caused or led to death)  
• Is life-threatening (i.e. the AE placed the subject at immediate risk of 
death; it does not apply to an AE which hypothetically might have caused 
the death if it were more severe)  
P h ase II b T L P L D C & I/II a T L P O v acci ne tri al   Versi o n 2. 4/ 1 5  Fe br u ary 2 0 2 1  
C o nfi de nti al  4 4  • R e q uir e s or pr ol o n g s i n p ati e nt h o s pit ali z ati o n (i. e., t h e A E r e q uir e d at l e a st 
a 2 4 -h o ur h o s pit ali z ati o n. (I n p ati e nt h o s pit ali z ati o n or pr ol o n g e d a 
h o s pit ali z ati o n b e y o n d t h e e x p e ct e d l e n gt h of st a y; h o s pit ali z ati o n s f or 
el e cti v e m e di c al/ s ur gi c al pr o c e d ur e s, s c h e d ul e d tr e at m e nt s, or r o uti n e 
c h e c k -u p s ar e n ot S A E s b y t hi s crit eri o n.)  
• I s di s a bli n g (i. e., t h e A E r e s ult e d i n a s u b st a nti al di sr u pti o n of t h e s u bj e ct’ s 
a bilit y t o c arr y o ut n or m al lif e f u n cti o n s)  
• I s a c o n g e nit al a n o m al y/ birt h d ef e ct (i. e., a n a d v er s e o ut c o m e i n a c hil d or 
f et u s of a s u bj e ct e x p o s e d t o t h e st u d y dr u g pri or t o c o n c e pti o n or d uri n g 
pr e g n a n c y)  
• D o e s n ot m e et a n y of t h e a b o v e s eri o u s crit eri a b ut m a y j e o p ar di z e t h e 
s u bj e ct a n d m a y r e q uir e m e di c al or s ur gi c al i nt er v e nt i o n t o pr e v e nt o n e of 
t h e o ut c o m e s li st e d a b o v e  
E x p e ct e d/  U n e x p e ct e d  D et er mi n ati o n:  
 
E x p e ct e d  A E s  ar e  t h o s e  A E s  t h at  ar e  li st e d  or  c h ar a ct eri z e d  i n  t h e  c urr e nt  
I n v e sti g at or  Br o c h ur e  (I B)  a n d/ or  ar e  li st e d  i n  t h e  i nf or m e d  c o n s e nt  d o c u m e nt.  
U n e x p e ct e d  A E s  ar e t h o s e  n ot  li st e d  i n  t h e  c urr e nt  I B  a n d/ or  i nf or m e d  c o n s e nt  
d o c u m e nt . T hi s  i n cl u d e s  A E s  f or  w hi c h  t h e  s p e cifi cit y  or  s e v erit y  i s  n ot  c o n si st e nt  
wit h  t h e  d e s cri pti o n  i n  t h e  I B.  F or  e x a m pl e,  u n d er  t hi s  d efi niti o n,  h e p ati c  n e cr o si s  
w o ul d  b e  u n e x p e ct e d  if  t h e  I n v e sti g at or  Br o c h ur e  o nl y  r ef err e d  t o  el e v at e d  h e p ati c  
e n z y m e s  or  h e p atiti s.  
 
St u d y  Dr u g  R el ati o n s hi p:  
 
T h e  Pri n ci p al  I n v e sti g at or  will  d et er mi n e  if  t h er e  i s  a p o s si bilit y  t h at  t h e  st u d y  dr u g  
c a u s e d  t h e  a d v er s e  e v e nt.  I n  t h e  r e p ort  t o  t h e  s p o n s or,  t h e  i n v e sti g at or  m u st  
i n cl u d e  a n  a s s e s s m e nt  of  c a u s alit y,  i. e .,  w h et h er  t h er e  i s  a p o s si bilit y  t h at  t h e  dr u g  
c a u s e d  t h e  e v e nt.  S o m e  fa ct or s  t h at  m a y  b e  c o n si d er e d  i n  d e t er mi ni n g  if  a n  A E  
s h o ul d  b e  r e g ar d e d  a s  p o s si bl y  r el at e d  t o  t h e  u s e  of  t h e  dr u g  c o m p o n e nt s  ar e  a s  
f oll o w s:  
 T h er e i s a cli ni c all y pl a u si bl e ti m e s e q u e n c e b et w e e n o n s et of t h e A E a n d 
a d mi ni str ati o n of dr u g c o m p o n e nt s;  
 T h er e i s a bi ol o gi c all y pl a u si bl e m e c h a ni s m f or dr u g c o m p o n e nt s t o c a u s e 
or c o ntri b ut e t o t h e A E;  
T h e A E c a n n ot b e attri b ut e d s ol el y t o c o n c urr e nt/ u n d erl yi n g ill n e s s, ot h er 
dr u g s, or pr o c e d ur e s.  
6. 2  R e p orti n g of Ad v er s e Ev e nt s As s o ci at e d wit h Thi s St u d y  
I n v e sti g at or s  ar e  r e q uir e d  t o  r e p ort  t o  t h e  s p o n s or  a n d/ or  s p o n s or’ s  
d e si g n at e d  r e pr e s e nt ati v e:  
 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  45 • Any adverse  event  that may be regarded  as caused  by, or possibly  
caused  by, the study  drug  
• All serious  adverse  events   
• All unanticipated  problems  involving  risks to human  subjects  or other s 
(UPIRSOs),  including  any adverse  event  that falls into this category  
• All serious  and unexpected  adverse  events  for which  there  is a reasonable  
possibility  that the adverse  event  was caused  by the study  drug (SUSARs)  
 
Investigators  are required  to report  to the Institutional  Review  Board  (IRB):   
 
• All unanticipated  problems  involving  risks to human  subjects  or others  
(UPIRSOs)  
• All adverse  events  that falls into the category  of UPIRSO.   An adverse  
event  is a UPIRSO  when  it is unexpected,  possibly  related  to participation  
in the research,  and places  the subject  or others  at a greater  risk of harm  
than was previously  known.   
• All serious  and unexpected  adverse  events  for which  there  is a reasonable  
possibility  that the adverse  event  was caused  by the study  drug (SUSARs)  
 
If an event  is reportable  under  21 CFR §312.32,  i.e., if the event  is a SUSAR,  the 
IND Sponsor  or sponsor’s  repres entative  will report  these  to the FDA per the 
requirements  of 21 CFR § 312.32.    
 
All events meeting the outlined criteria will be reported for the time period 
beginning with any amount of exposure to vaccine components through the 
protocol -defined follow -up period.  
6.3 Reporting Requirements for IND Sponsor  
6.3.1  MedWatch 3500A reporting guidelines  
For sponso rs of IND Studies , there are additional reporting requirements for the 
FDA in accordance with the regulations  set forth in 21  CFR § 312.32 .  If an event 
is reportable under the U.S. Code of Federal Regulations, the sponsor will submit 
a Form FDA 3500A (MedWatch), as required by regulation.  Form FDA 3500A 
Supplement provides general instructions for filling out the Form FDA 3500A , and 
should be used as guidance . Events meeting the following criteria need to be 
submitted to the FDA as expedited IND  Safety Reports according to the following 
guidance and timelines:  
7 Calendar -Day Telephone or Fax Report : The Sponsor is required to notify the 
FDA of any unexpected fatal or life -threatening suspected adverse reactions  as 
soon as possible, but no later than 7 calendar days after the sponsor’s initial receipt 
of the information.  
15 Calendar -Day Written Report : The Sponsor is required to notify the FDA and 
all participating investigators, in a written IND Safety Report, of any suspected 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  46 adverse reaction that is both serious  and unexpected .  The sponsor must report 
an adverse event as a suspected adverse reaction only if there is evidence to 
suggest a causal relationship between the drug and the adverse event.   
• Written IND Safety Reports should include an Analysis of Similar 
Events in accordance with regulation 21 CFR § 312.32. All safety 
reports previously filed w ith the IND concerning similar events 
should be analyzed and the significance of the new report in light of 
the previous, similar reports commented on.  
• Written IND safety reports with Analysis of Similar Events are to be 
submitted to the FDA and all partic ipating investigators within 15 
calendar days of first learning of the event. The FDA prefers these 
reports on a MedWatch 3500A Form but alternative formats are 
acceptable (e.g. , summary letter).  
Follow -up information:  
If any information necessary to eval uate the suspected unexpected serious 
adverse reaction  is missing or unknown, o r if new information becomes available, 
that information should be submitted as a Follow Up IND Safety Report as soon 
as the information is available, but no later than 15 calend ar days after the sponsor 
receives the information.   
Study  Drug  Relationship  Determination  for Reporting  Purposes : 
 
For reporting purposes, suspected adverse reactions are those where there is a 
reasonable possibility that the study drug caused the adverse event. For reporting 
purposes, “reasonable possibility” means there is evidence to suggest a causal 
relationship  between the drug and the adverse event .  See 21 CFR 312.32.    
7.0 INVESTIGATOR REQUIREMENTS  
7.1  Study Initiation  
Before the start of t his study, the following docu ments must be on file with the 
Sponsor  or Sponsor’s  representative:  
• Original U.S. Form FDA  1572 for each Principal Investigator  (for all 
studies conducted under U.S. Investigational New Drug [IND] 
regulations), signed by the Principal Investigator. The names of any 
sub-investigators must appear on this form , as well as all other 
information required by the form . 
• Current curriculum vitae of the Principal Investigator  
• Written documentation of IRB approval of protocol and informe d 
consent document  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  47 • A copy of the IRB -approved informed consent document  
• A signed Clinical Research Agreement  
• A signed investigator’s agreement (Appendix K) 
• Laboratory Documentation  
• All other essential documents  required to be obtained under the 
CFR and ICH  GCP, as applicable to this study  
7.2  Study Completion  
The following materials are requested by the sponsor  when the study is 
considered complete or terminated:  
• A summary, prepared by the Principal Investigator, of the study, 
and/or a study manuscript, and/or a study abstract submitted to 
scientific conferences.  
7.3  Informed Consent  
Informed consent form template s will be provided, and the final IRB -approved 
document must be provided t o the S ponsor or Sponsor’s representative for 
regulatory purposes. The info rmed consent document must be signed by the 
subject or the subject’s legally  authorized representative before his or her 
participation in the study. The case history for each subject shall document that 
informed consent was obt ained prior to participation in the study.  
Copies of the informed consent form document s must be provided to the subject 
or the subject's legally authorized representative. If applicable, it will be provided 
in a certified translation of the local languag e. 
Signed consent forms must rema in in each subject’s study file and must be 
available for verification by study monitors at any time.  
7.4 Institutional Review Board or Ethics Committee Approval  
This protocol, the informed consent document, and relevant supporting information 
must be submitted to the IRB for review and must be approved before the study is 
initiated. The study will be conducted in accordance with U.S. FDA, applicable 
national and local health authorities, and IRB requirements.  
The Principal Investigator is responsible for keeping the IRB apprised of the 
progress of the study and of any changes made to the protocol as deemed 
appropriate, but  in any case the IRB must be updated at least once a year.  
Investigators are required to prom ptly notify their respective IRB of events as 
described in this protocol in Sections 6.0, 6.1, and 6.2.  Some IRBs may have other 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  48 specific adverse event requirements to which investigators are expected to adhere. 
Investigators must immediately forward to their IRB any written safety report or 
update provided by the Sponsor  (e.g., IND safety report, IB, safety amendments 
and updates, etc.).  
Ethics and Regulatory Considerations  
The protocol will be reviewed and approved by the IRB or Independent Ethics 
Committee (IEC) of each participating center prior to study initiation. A list of 
IRB/IEC members should be obtained by the investigator and provided to the 
sponsor and sponsor repr esentative. Any documents that the IRB/IEC may need 
to fulfill its responsibilities, such as protocol amendments and/or information from 
the sponsor will be submitted to the IRB/IEC. The IRB/IEC’s written unconditional 
approval of the study protocol and th e informed consent form will be in the 
possession of the PI and the Sponsor before the study is initiated. The IRB/IEC’s 
unconditional approval statement will be transmitted by the investigator or 
designee to the sponsor/sponsor representative prior to shi pment of study  drug 
supplies to the site. This approval document must refer to the study by exact 
protocol title and protocol version number/date and must identify the documents 
reviewed and the date of review.  
Protocol modifications or changes may not be initiated without prior written 
IRB/IEC approval except when necessary to eliminate immediate hazard to the 
patients. Such modifications will be submitted to the IRB/IEC and written 
verification that the modification was submitted and IRB/IEC 
acknowledgeme nt/approval should be obtained and transmitted to the 
Sponsor/Investigator or Sponsor/Investigator’s representative. The IRB/IEC must 
be informed by the principal investigator of any changes or revisions of informed 
consent form s or other documents origina lly submitted for review; adverse events 
and other reportable events as described in this protocol in Sections 6.0, 6.1, and 
6.2; any new information that may affect adversely the safety of the patients or the 
conduct of the study; annual updates and/or  request for re -approval; and when the 
study has been completed.  
7.5 Study Monitoring Requirements  
Site visits may be conducted by authorized Sponsor representative or CRO 
repre sentatives to inspect study data, subjects’ medical records, and  CRFs in 
accordance with current U.S. GCPs and the respective local and national 
government regulations and guidelines (if applicable).  
The Principal Investigator will permit authorized representatives of Sponsor , CRO, 
the FDA, and the respective national o r local health authorities to inspect facilities 
and records re levant to this study.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  49 7.6 Data Safety Monitoring Plan  
A DSMP  (Appendix  H) describing the CRO internal  monitoring plan includes data 
safety and integrity and site initiation/QA monitoring, as well as external monitoring 
plan, the Data Safety Monitoring Boar d (DSMB) charter and responsibilities.  
7.7  Study Medication Accountability  
The study drug will be provided by the Sponsor .  The recipient will  acknowledge 
receipt of the drug by returning th e INDRR -1 form indicating shipment content and 
condition. Damaged supplies will be replaced. Accurate records of all study drug 
dispensed from and returned to the study site should be recorded by using the 
institution’s drug inventory log or the NCI drug a ccountability log.   All partially used 
or empty containers should be disposed of at the study site according to 
institutional standard operating procedure. Return unopened, expired, or unused 
study drug with the Inventory of Returned Clinical Material form  as directed by  the 
Sponsor . 
7.8  Disclosure of Data  
Subject medical information obtained by this study is confidential, and disclosure 
to third parties other than those noted above is prohibited. Upon the subject’s 
permission, medical information may be given to his or her personal  physician or 
other appropriate medical personnel responsible for his or her welfare. Data 
generated by this study must be available for inspection upon request by 
representatives of the FDA, national and local health authoritie s, the Sponsor , and 
the IRB for each study site, if appropriate.  
7.9  Retention of Records  
U.S. FDA regulations (21 CFR §312.62[c]) require that records and documents 
pertaining to the conduct of this study and the distribution of investigational drug, 
including CRFs, consent forms, laboratory test results, and medication inventory 
records, must  be retained by the Principal Investigator for two years after 
marketing application approval. If no application is filed, these records must be 
kept two years after the investigation is discontinued and the FDA and the 
applicable national and local health  authorities are notified. The Sponsor will notify 
the Principal Investigator of these events.  
For studies conducted outside the United States under a U.S. IND, the Principal 
Investigator must comply with U.S. FDA IND regulations and with the record 
reten tion policies of the relevant national and local health authorities.  
7.10  Publications  
The investigator must agree to send to the Sponsor or Sponsor’s representative, 
for review all manuscripts, abstracts and presentations using data from this study 
prior to their submission. The Sponsor  or Sponsor’s representative reserves the 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  50 right to delete from such materials any part or parts deemed to be confidential or 
proprietary.  
7.11  Changes to Protocol  
The protocol may not be modified without written approval  of the Sponsor or 
Sponsor ’s representative, or the Study D irector. All changes to the protocol must 
be submitted to the FDA, the overseeing IRB, and local IRB/IEC. Additionally, 
changes must be approved by overseeing IRB prior to their implementation. 
Documentation of IRB/IEC approval must be sent to the Sponsor or Sponsor’s 
representative, and the Study Director immediately upon receipt.  Any changes 
and modifications to the informed consent language must be reviewed and 
approved by the Sponsor or Sponsor ’s representative, and the Study Director prior 
to submission to the local IRB.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  51 REFERENCES  
 
1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J 
Med 2004; 351:998 -1012.  
2. DR P, EA G. Cytokines: biology and applications in cancer medicine. In: al 
JHEFIRBJe, ed. Cancer Medicine 4th Editions, 1997:1213 -26. 
3. Philip PA, Flaherty L. Treatment of malignant melanoma with interleukin -2. 
Semin Oncol 1997; 24:S32 -8. 
4. Smith FO, Dow ney SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula 
US, Hughes MS, Restifo NP, Levy CL, et al. Treatment of metastatic melanoma using 
interleukin -2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14:5610 -8. 
5. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High -dose recombinant 
interleukin -2 therapy in patients with metastatic melanoma: long -term survival update. 
The cancer journal from Scientific American 2000; 6 Suppl 1:S11 -4. 
6. Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, P apadopoulos N. 
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, 
vinblastine and dacarbazine (CVD) and biotherapy using interleukin -2 and interferon -
alpha. Ann Oncol 1996; 7:827 -35. 
7. Legha SS, Ring S, Eton O, Bedikian A, B uzaid AC, Plager C, Papadopoulos N. 
Development of a biochemotherapy regimen with concurrent administration of cisplatin, 
vinblastine, dacarbazine, interferon alfa, and interleukin -2 for patients with metastatic 
melanoma. J Clin Oncol 1998; 16:1752 -9. 
8. O'Day SJ, Boasberg PD, Piro L, Kristedja TS, Wang HJ, Martin M, Deck R, Ames 
P, Shinn K, Kim H, et al. Maintenance biotherapy for metastatic melanoma with 
interleukin -2 and granulocyte macrophage -colony stimulating factor improves survival for 
patients resp onding to induction concurrent biochemotherapy. Clin Cancer Res 2002; 
8:2775 -81. 
9. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, 
Kirkwood JM, Eastern Cooperative Oncology G. Phase III trial comparing concurrent 
biochemotherapy with  cisplatin, vinblastine, dacarbazine, interleukin -2, and interferon 
alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic 
malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology 
Group. J Clin Onc ol 2008; 26:5748 -54. 
10. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with 
biochemotherapy for the treatment of metastatic melanoma: a meta -analysis of 18 trials 
involving 2,621 patients. J Clin Oncol 2007; 25:5426 -34. 
11. Bajetta E, Del  Vecchio M, Nova P, Fusi A, Daponte A, Sertoli MR, Queirolo P, 
Taveggia P, Bernengo MG, Legha SS, et al. Multicenter phase III randomized trial of 
polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus 
subcutaneous interleukin -2 and interfer on-alpha2b in metastatic melanoma. Ann Oncol 
2006; 17:571 -7. 
12. Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle 
TM, Schmittel A, Schadendorf D, et al. Dacarbazine, cisplatin, and interferon -alfa-2b with 
or without interleukin -2 in metastatic melanoma: a randomized phase III trial (18951) of 
the European Organisation for Research and Treatment of Cancer Melanoma Group. J 
Clin Oncol 2005; 23:6747 -55. 
13. Ridolfi R, Chiarion -Sileni V, Guida M, Romanini A, Labianca R, Freschi A, L o Re 
G, Nortilli R, Brugnara S, Vitali P, et al. Cisplatin, dacarbazine with or without 
subcutaneous interleukin -2, and interferon alpha -2b in advanced melanoma outpatients: 
results from an Italian multicenter phase III randomized clinical trial. J Clin On col 2002; 
20:1600 -7. 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  52 14. NCCN Practical Guidelines in Oncology: Melanoma. National Comprehensive 
Cancer Network 2014; Version 3.2014.  
15. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of 
long-term adjuvant therapy with inter feron alpha -2a in patients with regional node 
metastases from cutaneous melanoma: a randomised trial. Lancet 2001; 358:866 -9. 
16. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton 
MR, Thatcher N, Lorigan PC, Marsden JR, et al. Adj uvant interferon in high -risk 
melanoma: the AIM HIGH Study --United Kingdom Coordinating Committee on Cancer 
Research randomized study of adjuvant low -dose extended -duration interferon Alfa -2a in 
high-risk resected malignant melanoma. J Clin Oncol 2004; 22: 53-61. 
17. Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger 
W, Aubock J, Fritsch P, Kerl H, et al. Adjuvant interferon alfa -2a treatment in resected 
primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative 
Group. J Clin Oncol 1998; 16:1425 -9. 
18. Grob JJ, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, 
Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, et al. Randomised trial of interferon 
alpha -2a as adjuvant therapy in resected primary melanom a thicker than 1.5 mm without 
clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 
1998; 351:1905 -10. 
19. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. 
Interferon alfa -2b adjuvant therapy of high -risk resected cutaneous melanoma: the 
Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7 -17. 
20. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, 
Smith TJ, Rao U, Steele M, Blum RH. High - and low -dose interfero n alfa -2b in high -risk 
melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 
18:2444 -58. 
21. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U, Eastern 
Cooperative Oncology G. A pooled analysis of eastern cooperati ve oncology group and 
intergroup trials of adjuvant high -dose interferon for melanoma. Clin Cancer Res 2004; 
10:1670 -7. 
22. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, 
Sales F, Gore M, Mackie R, et al. Adjuvant therapy with  pegylated interferon alfa -2b 
versus observation alone in resected stage III melanoma: final results of EORTC 18991, 
a randomised phase III trial. Lancet 2008; 372:117 -26. 
23. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, 
Gonzalez R, Rob ert C, Schadendorf D, Hassel JC, et al. Improved survival with 
ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 -23. 
24. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, Lebbe C, Baurain 
JF, Testori A, Grob JJ, et al. Ipi limumab plus dacarbazine for previously untreated 
metastatic melanoma. N Engl J Med 2011; 364:2517 -26. 
25. Ipilimumab or High -Dose Interferon Alfa -2b in Treating Patients With High -Risk 
Stage III -IV Melanoma That Has Been Removed by Surgery. 
http://www.cli nicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?term=A+Phase+III+Randomized+S
tudy+of+Adjuvant+Ipilimumab+Anti -CTLA4+Therapy&rank=1: ClinicalTrials.gov.  
26. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, 
Powderly JD, Carvajal RD, Sosman JA, At kins MB, et al. Safety, activity, and immune 
correlates of anti -PD-1 antibody in cancer. N Engl J Med 2012; 366:2443 -54. 
27. Taneja SS. Re: Safety and activity of anti -PD-L1 antibody in patients with 
advanced cancer. The Journal of urology 2012; 188:2148 -9. 
28. Topalian SL, Drake CG, Pardoll DM. Targeting the PD -1/B7-H1(PD -L1) pathway 
to activate anti -tumor immunity. Current opinion in immunology 2012; 24:207 -12. 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  53 29. Mario Sznol HMK, F. Stephen Hodi, David F. McDermott, Richard D. Carvajal, 
Donald  P. Lawrence, Suzanne Louise Topalian, Michael B. Atkins, John D. Powderly, 
William Howard Sharfman, Igor Puzanov, David C. Smith, Jon M. Wigginton, Georgia 
Kollia, Ashok Kumar Gupta, Jeffrey Alan Sosman. Survival and long -term follow -up of 
safety and resp onse in patients (pts) with advanced melanoma (MEL) in a phase I trial of 
nivolumab (anti -PD-1; BMS -936558; ONO -4538). J Clin Oncol 31, 2013 (suppl; abstr 
CRA9006^) 2013.  
30. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal 
NH, Ar iyan CE, Gordon RA, Reed K, et al. Nivolumab plus ipilimumab in advanced 
melanoma. N Engl J Med 2013; 369:122 -33. 
31. ClinicalTrials.gov. Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab 
Versus Ipilimumab Alone in Previously Untreated Advanced Melan oma (CheckMate 
067). http://clinicaltrials.gov/ct2/show/NCT0184450.  
32. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern 
CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel -T immunotherapy for castration -
resistant prostate cancer.  N Engl J Med 2010; 363:411 -22. 
33. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, 
Old LJ. A survey of the humoral immune response of cancer patients to a panel of 
human tumor antigens. J Exp Med 1998; 187:1349 -54. 
34. Sahin  U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, 
Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune 
responses in the autologous host. Proc Natl Acad Sci U S A 1995; 92:11810 -3. 
35. Gabrilovich DI, Che n HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, 
Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human 
tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096 -103. 
36. Ishida T, Oyama T, Carbone DP, Gabrilovich DI. Defective function of 
Langerhans cells in tumor -bearing animals is the result of defective maturation from 
hemopoietic progenitors. J Immunol 1998; 161:4842 -51. 
37. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, 
Kufe D. Fusions of human ovarian carcinoma cells with autologous or allogeneic 
dendritic cells induce antitumor immunity. J Immunol 2000; 165:1705 -11. 
38. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal 
RG. Dendritic cells gen etically modified with an adenovirus vector encoding the cDNA 
for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 
1997; 186:1247 -56. 
39. Specht JM, Wang G, Do MT, Lam JS, Royal RE, Reeves ME, Rosenberg SA, 
Hwu P. Dendritic c ells retrovirally transduced with a model antigen gene are 
therapeutically effective against established pulmonary metastases. J Exp Med 1997; 
186:1213 -21. 
40. Li J, Holmes LM, Franek KJ, Wagner TE, Wei Y. Murine tyrosinase expressed by 
a T7 vector in bone  marrow -derived dendritic progenitors effectively prevents and 
eradicates melanoma tumors in mice. Cancer gene therapy 2000; 7:1448 -55. 
41. Wei Y, Li J, Chen WY, Yu X, Sticca RP, Wagner TE. Enhanced transgene 
expression and effective in vivo antitumor immu ne responses initiated by dendritic 
progenitors transfected with a nonviral T7 vector expressing a model tumor antigen. J 
Immunother 2000; 23:75 -82. 
42. Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, Audring H, Guo 
Y, Sterry W, Walden P. Hy brid cell vaccination for cancer immune therapy: first clinical 
trial with metastatic melanoma. Int J Cancer 2000; 85:618 -26. 
43. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian 
SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, et  al. Immunologic and therapeutic 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  54 evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic 
melanoma. Nat Med 1998; 4:321 -7. 
44. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, 
Robinson WA, Flaherty LE, Richa rds JM, Bartolucci AA, et al. A phase III randomized, 
double -blind multiinstitutional trial of vaccinia melanoma oncolysate -active specific 
immunotherapy for patients with stage II melanoma. Cancer 1995; 75:34 -42. 
45. Bystryn JC. Clinical activity of a pol yvalent melanoma antigen vaccine. Recent 
Results Cancer Res 1995; 139:337 -48. 
46. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific 
immunotherapy. Semin Oncol 1998; 25:623 -35. 
47. Morton DL, Hoon DS, Nizze JA, Foshag LJ, Famatiga E , Wanek LA, Chang C, 
Irie RF, Gupta RK, Elashoff R. Polyvalent melanoma vaccine improves survival of 
patients with metastatic melanoma. Annals of the New York Academy of Sciences 1993; 
690:120 -34. 
48. Berd D, Kairys J, Dunton C, Mastrangelo MJ, Sato T, Mag uire HC, Jr. 
Autologous, hapten -modified vaccine as a treatment for human cancers. Semin Oncol 
1998; 25:646 -53. 
49. Berd D, Maguire HC, Jr., Schuchter LM, Hamilton R, Hauck WW, Sato T, 
Mastrangelo MJ. Autologous hapten -modified melanoma vaccine as postsurg ical 
adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997; 15:2359 -70. 
50. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by 
immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558 -61. 
51. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against 
poorly immunogenic tumors by immunization with dendritic cell -tumor fusion vaccines. J 
Immunol 1998; 161:5516 -24. 
52. Lespagnard L, Mettens P, Verheyden AM, Tasiaux N, Thielemans  K, van 
Meirvenne S, Geldhof A, De Baetselier P, Urbain J, Leo O, et al. Dendritic cells fused 
with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer 1998; 76:250 -
8. 
53. Cao X, Zhang W, Wang J, Zhang M, Huang X, Hamada H, Chen W. Therap y of 
established tumour with a hybrid cellular vaccine generated by using granulocyte -
macrophage colony -stimulating factor genetically modified dendritic cells. Immunology 
1999; 97:616 -25. 
54. Zhang JK, Li J, Zhang J, Chen HB, Chen SB. Antitumor immunoprev entive and 
immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and 
hepatocarcinoma in vivo. World J Gastroenterol 2003; 9:479 -84. 
55. Kawada M, Ikeda H, Takahashi T, Ishizu A, Ishikura H, Katoh H, Yoshiki T. 
Vaccination of fusion cells of rat dendritic and carcinoma cells prevents tumor growth in 
vivo. Int J Cancer 2003; 105:520 -6. 
56. McConnell EJ, Pathangey LB, Madsen CS, Gendler  SJ, Mukherjee P. Dendritic 
cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor 
model. The Journal of surgical research 2002; 107:196 -202. 
57. Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, Gong J. Prevention of 
spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion 
cells. J Immunol 2003; 170:1980 -6. 
58. Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler SJ, 
Kufe D, Gong J. Immunotherapy of spontaneous mammary  carcinoma with fusions of 
dendritic cells and mucin 1 -positive carcinoma cells. Immunology 2003; 109:300 -7. 
59. Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D. Activation of 
antitumor cytotoxic T lymphocytes by fusions of human dendritic cel ls and breast 
carcinoma cells. Proc Natl Acad Sci U S A 2000; 97:2715 -8. 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  55 60. Marten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, 
Hanfland P, Von Ruecker A, et al. Allogeneic dendritic cells fused with tumor cells: 
preclinical re sults and outcome of a clinical phase I/II trial in patients with metastatic 
renal cell carcinoma. Hum Gene Ther 2003; 14:483 -94. 
61. Holmes LM, Li J, Sticca RP, Wagner TE, Wei Y. A Rapid, Novel Strategy to 
Induce Tumor Cell -Specific Cytotoxic T Lymphocyte  Responses Using Instant 
Dendritomas. Journal of immunotherapy : official journal of the Society for Biological 
Therapy 2001; 24:122 -9. 
62. Li J, Holmes LM, Franek KJ, Burgin KE, Wagner TE, Wei Y. Purified hybrid cells 
from dendritic cell and tumor cell fu sions are superior activators of antitumor immunity. 
Cancer Immunol Immunother 2001; 50:456 -62. 
63. Wei YC, Sticca RP, Li J, Holmes LM, Burgin KE, Jakubchak S, Bouton -Verville 
H, Williamson J, Meyer K, Evans L, et al. Combined treatment of dendritoma vacci ne 
and low -dose interleukin -2 in stage IV renal cell carcinoma patients induced clinical 
response: A pilot study. Oncol Rep 2007; 18:665 -71. 
64. Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, Evans L, Smith SJ, 
Stephenson JJ, Wagner TE. Dendri toma vaccination combined with low dose 
interleukin -2 in metastatic melanoma patients induced immunological and clinical 
responses. Int J Oncol 2006; 28:585 -93. 
65. Sun W, Schuchter LM. Metastatic melanoma. Current treatment options in 
oncology 2001; 2:193 -202. 
66. Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, 
Dorey FJ, Gitlitz BJ, Figlin RA, et al. Number of metastatic sites rather than location 
dictates overall survival of patients with node -negative metastatic renal cell carc inoma. 
Urology 2003; 61:314 -9. 
67. Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott 
D, Smith T, et al. Fusion cell vaccination of patients with metastatic breast and renal 
cancer induces immunological and clinical responses. Cl in Cancer Res 2004; 10:4699 -
708. 
68. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, Gilboa E, Lyerly HK. 
Induction of tumor -specific cytotoxic T lymphocytes in cancer patients by autologous 
tumor RNA -transfected dendritic cells. Ann Surg 2002; 235: 540-9. 
69. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, 
Schadendorf D. Vaccination of melanoma patients with peptide - or tumor lysate -pulsed 
dendritic cells. Nat Med 1998; 4:328 -32. 
70. Banchereau J, Palucka AK, Dhodapkar M, Burkeho lder S, Taquet N, Rolland A, 
Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, et al. Immune and clinical responses 
in patients with metastatic melanoma to CD34(+) progenitor -derived dendritic cell 
vaccine. Cancer Res 2001; 61:6451 -8. 
71. Timmerman JM, Singh  G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, 
Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. Immunogenicity of a plasmid DNA 
vaccine encoding chimeric idiotype in patients with B -cell lymphoma. Cancer Res 2002; 
62:5845 -52. 
72. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, 
Chang AE, Braun TM, Mule JJ. Vaccination of pediatric solid tumor patients with tumor 
lysate -pulsed dendritic cells can expand specific T cells and mediate tumor regression. 
Cancer Res 2001; 61:8513 -9. 
73. Schuler -Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, 
Bender A, Feuerstein B, Fritsch PO, Romani N, et al. Rapid induction of tumor -specific 
type 1 T helper cells in metastatic melanoma patients by vaccination with mature, 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  56 cryopreserv ed, peptide -loaded monocyte -derived dendritic cells. J Exp Med 2002; 
195:1279 -88. 
74. Eisenhauer E a., Therasse P, Bogaerts J, et al. New response evaluation criteria 
in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 
2009;45(2):228 -247.  
75. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response 
criteria for use in trials testing immunotherapeutics. The Lancet Oncology. 
2017;18(3):e143 -52. 
 
 
Phase IIb TLPLDC & TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  57 Appendix A  
 
Trial Schema  
 
Study Population 
Adjuvant Melanoma 
patient s, n=140, 
randomized 2:1 
(vacci ne:control) 
• Stage III and I V 
(resected) 
• NED after standa rd of 
care (SOC ) 
• Sufficient tu mor (1  mg/1 
cm3) available to 
produce vacci ne 
• Stratified b y Stage 
• Crossove r – open label 
treatment of recurred 
controls 
0 1 
2 
  Endpoin ts 
  1o            2o 
DFS     DF S/OS 
Tumor Lysa te 
Loaded YCWP 
+ DC 
+ DC 
Empty YCWP 
Dosing  
by Month 
6 A pro spective, randomi zed, blinded, place bo-contro lled, phase  IIb 
trial of an autologous tumor lysate (TL)+yea st cell wall part icles 
(YCWP)+dend ritic ce lls (DC) vacci ne vs unloaded YCWP+DC in 
stage III and st age IV (resected) melanoma  to pre vent recurrence 
12 18 24 36 
Phase IIb TLPLDC & TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  58  
Appendix B  
 
Combined  Trial Schema  
 
  
Combined	 Trials	 Schema
Melanoma
Stage	 III
Stage	 IV	
(resected)R
A
N
D
O
M
I
Z
A
T
I
O
N
Controls
(n=40)
TLPLDC
(n=80)
TLPLDC
(n=20)
TLPO	
Phase	 I/IIa
(n=40)TLPLDC	 	 Phase	 IIbTrial
n=120
Combined	 Trials
n=601
2
1
2Primary	
Analysis
(n=120)
TLPLDC
(n=100)Per	
Treatment	
Analysis
(n=140)
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  59 Appendix C 
 
Vaccination Timeline  
 
1 2 6 12 18 24 36 0Vax1 Vax2 Vax3Booster
x1Booster
x2Booster
x3
RO R1 R2 R3 RB1 RB2 RB3Before 
1st
vaccine
Serum & 
Blood 
sampleSerum & 
Blood 
sampleSerum & 
Blood 
sampleSerum & 
Blood 
sampleSerum & 
Blood 
sampleSerum & 
Blood 
sampleSerum & 
Blood 
sampleMONTHS 
Phase 
 IIb
Clinical Schedule
Consent #1
Tumor Acquisition
Consent #2
Blood for DC
Randomization
First vaccination
3wks-3mos from
Completion of SoCDFS DFS/OSPrimary
EndpointSecondary
Endpoint
Vax2-3 given +1wk Booster 1- 3 given +2wk
Phase IIb TLPLDC & TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  60  
Appendix C 
 
Open Label Vaccination Timeline  
 
 

Phase IIb TLPLDC & TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  61 Appendix D 
 
NCI Common Terminology Criteria for Adverse Events, v4.03  
 
obtained from http://ctep.cancer.gov/forms/CTCAEv4.03.pdf  
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06 14_QuickReference_8.5x11.pdf  
  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  62 Appendix E 
 
ECOG Performance Status Criteria  
 
Score  Description  
0 Fully active, able to carry on all pre -disease performance 
without restriction  
1 Restricted in physically strenuous activity but ambulatory 
and able to carry out work of a light or sedentary nature, 
e.g., light housework, office work  
2 Ambulatory and capable of all self-care but unable to carry 
out any work activities.  Up and about more than 50% of 
waking hours.  
3 Capable of only limited self-care, confined to bed or chair 
more than 50% of waking h ours 
4 Completely disabled.  Cannot carry on any self-care.  Totally 
confined to bed or chair.  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  63 Appendix F 
 
1. Quick Reference for the Response Evaluation Criteria in Solid Tumors 
(RECIST Criteria)  
 
 
A. Indications for use of RECIST Criteria  
- The RECIST criteria is useful in all trials where objective response is the 
primary study endpoint, as well as in trials where assessment of stable 
disease, tumor progression or time to progression analyses are 
undertaken, since all of these outcome measures a re based on an 
assessment of anatomical tumor burden and its change on the study.  
 
B. Identification of Lesions  
I. Measurable disease  
- All patients must have measurable disease to be enrolled into this trial.  
- All baseline imaging for determining these target lesi ons must be 
completed no more than 4 weeks  prior to beginning treatment  
- Measurable disease includes:  
▪ Tumors that can be accurately measured along the 
longest  diameter  
▪ Tumors must be >10mm by CT (CT must use 5mm cuts or 
smaller)  
▪ If tumor lesions are measur ed on clinical exam, the lesion 
should be superficial, >10mm in diameter when measured 
by a caliber  
▪ Tumors must be >20mm by chest xray.  
 
II. Lymph nodes must be measured along its shortest  axis  
▪ Nodes must be >15mm by CT scan (CT must use 5mm 
cuts or smaller)  
 
III. Target lesions  
- Target lesions must be determined by each primary investigator  
- Baseline imaging must be completed no more than 4 weeks before 
initiation of trial  
- All target lesions must be measurable tumors that are easily monitored 
with reproducible repeated measurements.  
▪ Maximum of 5 target lesions  
▪ Maximum of 2 lesions per organ   
▪ A sum of all the diameters for each target lesion is 
recorded and monitored throughout the study forming a 
baseline sum of diameters . 
- All other lesions will be deemed non -target lesions.  They may be 
followed throughout the trial, but will not be incorporated into the 
baseline sum of diameters.  These non -target tumors must be recorded 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  64 separately.  
IV. Imaging Modalities  
- All lesions must be measurable  per iRECIST 1.1 Criteria .  It is preferred 
to monitor each lesion with an imaging study if able.   
▪ CT scans must be completed as IV contrast and a 5mm 
cuts.  
▪ MRI may also be used.  
▪ FDG -PET useful in monitoring lesions.  It should be 
combined with a  CT scan for complete evaluation of 
tumors.  
C. Evaluation of Tumor Response  
- Tumor response of target lesions include:  
▪ Complete response (CR): Disappearance of all target 
lesions.  Any pathologic lymph nodes must be <10mm 
(target or non -target nodes).  
▪ Partia l Response (PR): At least a 30% decrease  in the 
sum of diameters for target lesions in comparison to 
baseline sum of diameters.  
▪ Progressive Disease (PD): At least a 20% increase  in the 
sum of diameters for target lesions.  In addition to this 
increase, the  sum of diameters must increase by at least 
5mm.  The development of new lesions is also evidence 
of PD.  
▪ Stable Disease (SD): Tumors neither fit criteria for PR or 
PD. 
- Tumor response of non -target lesions include:  
▪ CR - Disappearance of all target lesions.  Any pathologic 
lymph nodes must be <10mm (target or non -target nodes).  
▪ Non-CR/Non -PD - Persistence of one or more non -target 
lesions and maintenance of tumor marker level above the 
normal limits.  
▪ PD – Unequivocal progression of existing non -target 
tumors,  or the appearance of new lesions.  
- The primary investigator at each site will verify the presence of changes 
in target/non -target lesions.   
- Target lesions which shrink, and are deemed too small to measure 
should be given a default measurement of 5mm.   
- If target lesions have completely disappeared is should be measured as 
0mm.   
- Lymph nodes may regress to <10mm but because they are still 
measurable, the sum of diameters may never equal 0mm in the setting 
of CR when they are included as target lesions.  
- Please see table below regarding  the Best overall response  
 
 
Target lesions  Non-Target lesions  New Lesions  Overall response  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  65 CR CR No CR 
CR Incomplete 
response/SD  No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
 
 
* Please refer to the complete New response evaluation criteria in solid tumors: 
Revised RECIST guidelines – version 1.1 for further details74.  
 
2. Quick Reference for iRECIST Criteria  
 
A. Indications:  
- The guidelines continue to recommend use of RECIST 1.1 to define 
whether tumor lesions are measurable or non -measurable and the 
principles used to determine objective tumor response are largely 
unchanged from RECIST 1.1. The concept change for iRECIST is t he 
resetting the bar if RECIST 1.1 progression is followed at the next 
assessment by tumor shrinkage.  
-iRECIST defines  unconfirmed progress (i UPD ) on the basis of RECIST 1.1 
principles; however, iUPD requires confirmation, which is done on the basis 
of obs erving either a further increase in size (or in the number of new 
lesions) in the lesion category in which progression was first identified in (ie, 
target or non -target disease), or progression (defined by RECIST 1.1) in 
lesion categories that had not prev iously met RECIST 1.1 progression 
criteria. However, if progression is not confirmed, but instead tumor  
shrinkage occurs (compared with baseline), which meets the criteria of iCR, 
iPR, or iSD, then the bar is reset so that iUPD needs to occur again 
(compar ed with nadir values) and then be confirmed (by further growth) at 
the next assessment for iCPD to be assigned. If no change in tumor  size or 
extent from iUPD occurs, then the time point  response would again be 
iUPD. This approach allows atypical responses , such as delayed responses 
that occur after pseudoprogression, to be identified, further understood, and 
better characterized . 
-However, many aspects of new lesion assessment are unique to iRECIST . 
If a new lesion is identified (thus meeting the criteria for iUPD) and the 
patient is clinically stable, treatment should be continued. New lesions 
should be assessed and categorized  as measurable or non -measurable 
using RECIST 1.1 principles.  
-The algo rithm for patients with no previous iUPD is identical to RECIST 
1.1. For patients with iUPD at the last timepoint response, the next timepoint 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  66 response is dependent on the status of all lesions, including target, non -
target, new lesion target, and new lesi on non -target; on whether any 
increase in size has occurred (either a further increase in size or a sufficient 
increase to assign a new iUPD if the criteria were not previously met); or 
the appearance of additional new lesions.  
 
B. Identification of tumors , refer to RECIST 1.1  
 
C. Assignment of time point response using iRECIST26 
 Time 
point 
response 
with no 
previous 
iUPD in 
any 
category  Time 
point 
response 
with 
previous 
iUPD in 
any 
category *  
Target lesions: iCR; non -target 
lesions: iCR ; new lesions: no  iCR iCR 
Target lesions: iCR; non -target 
lesions: non -iCR/non -iUPD; 
new lesions: no  iPR iPR 
Target lesions: iPR; non -target 
lesions: non -iCR/non -iUPD; 
new lesions: no  iPR iPR 
Target lesions: iSD; non -target 
lesions: non -iCR/non -iUPD;  
new lesions: no  iSD iSD 
Target lesions: iUPD with no 
change, or with a decrease 
from last timepoint; non -target 
lesions: iUPD with no change, 
or decrease from last 
timepoint; new lesions: yes  Not 
Applicable  New lesions 
confirm iCPD  
if new 
lesions were 
previously 
identified and 
they have 
increased in 
size (≥5 mm 
in sum of 
measures for 
new lesion 
target or any 
increase for 
new lesion 
non-target) 
or number; if 
no change is 
seen in new 
lesions (size 
or number) 
from last 
timepoint, 
assig nment 
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  67 remains 
iUPD  
Target lesions: iSD, iPR, iCR; 
non-target lesions: iUPD; new 
lesions: no  iUPD  Remains 
iUPD unless 
iCPD  is 
confirmed on 
the basis of a 
further 
increase in 
the size of 
non-target 
disease 
(does not 
need to meet 
RECIST 1.1 
criteria for 
unequivocal 
progression)  
Target lesions: iUPD; non -
target lesions: non -iCR/non -
iUPD, or iCR; new lesions: no  
 iUPD  Remains 
iUPD unless 
iCPD is 
confirmed on 
the basis of a 
further 
increase in 
sum of 
measures ≥5 
mm; 
otherwise, 
assignment 
remains 
iUPD  
Target lesions: iUPD; non -
target lesions: iUPD; new 
lesions: no  
 iUPD  Remains 
iUPD unless 
iCPD  is 
confirmed 
based on a 
further 
increase in 
previously 
identified 
target lesion 
iUPD in sum 
of measures 
≥5 mm or 
non-target 
lesion iUPD 
(previous 
assessment 
need not 
have shown 
unequivocal 
progression)  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  68 Target lesions: iUPD; non -
target lesions: iUPD; new  
lesions: yes  
 iUPD  Remains 
iUPD unless 
iCPD is 
confirmed on 
the basis of a 
further 
increase in 
previously 
identified 
target lesion 
iUPD sum of 
measures ≥5 
mm, 
previously 
identified 
non-target 
lesion iUPD 
(does not 
need to be 
unequivocal), 
or an 
increase in 
the size or 
number of 
new lesions 
previously 
identified  
Target lesions: non -iUPD or 
progression; non -target 
lesions: non -iUPD or 
progression; new lesions: yes  iUPD  Remains 
iUPD unless 
iCPD is 
confirmed on 
the basis of 
an increase 
in the size or 
numbe r of 
new lesions 
previously 
identified  
Target lesions, non -target lesions, and new lesions defined 
according to RECIST 1.1 principles; if no pseudoprogression 
occurs, RECIST 1.1 and iRECIST categories for complete 
response, partial response, and stable d isease would be the 
same. *Previously identified in assessment immediately 
before this timepoint. “i” indicates immune responses 
assigned using iRECIST. iCR=complete response. 
iPR=partial response. iSD=stable disease. 
iUPD=unconfirmed progression. non -iCR/non-iUPD=criteria 
for neither CR nor PD have been met. iCPD=confirmed 
progression. RECIST=Response Evaluation Criteria in Solid 
Tumors.  
 
 
* Please refer to the complete Guidelines for iRECIST.75   
  
Phase IIb TLPLDC & TLPO vaccine trial   Version 2.4/ 15 February 2021  
69 
 Appendix G  
 
Schedule of Events  
 

Phase IIb TLPLDC & TLPO vaccine trial   Version 2.4/ 15 February 2021  
70 
 Open Label Protocol Schedule  of Events  
 
 
CLINIC VISIT   
PROCEDURES   
TOTAL  
Visit #  Time Req     
(hr)  
Time Point   
Purpose   
Screening   
History  Nursing  
Visit  
UPT Blood  
Draws  Inoculation  # of Shots  
This Visit Time for 
Inoc + 
Follow -Ups 
1 2 Pre-treatment  Consent/Tissue Procurement  
Gather Baseline Data  x x x x   0 N/A 
2 2 Baseline  Consent/Randomization & Treatment  
Neupogen Injection  
Gather Current Baseline Data  x x x x  X 
(Neupogen 
injection)  1 N/A 
3 1 Baseline  Draw Blood to Obtain Dendritic Cells   x x  x  0 N/A 
 
START  PRE-INOCULATION  BLOOD  DRAWS  AND  ADMINISTRATION  OF INOCULATIONS  
4 1 Starting Time 
Point  Draw blood for Immunologic Sample R0  
Administer Inoculation #1   x x x x x 2  
1 hr  
5 1 Week 4  
+ 1 week  Draw blood to record immunologic levels pre -inoculation #2  
Administer Inoculation #2   x x x x x 2  
1 hr  
6 1 Week 8  
+ 1 week  Draw blood to record immunologic levels pre -inoculation #3  
Administer Inoculation #3   x x x x x 2  
1 hr  
7 1 Week 12  
+ 1 week  Draw blood to record immunologic levels pre -inoculation #4  
Administer Inoculation #4   x x x x x 2 1 hr 
 
START PRE -BOOSTER BLOOD DRAWS AND ADMINISTRATION OF BOOSTERS  
8 1 Month 6 from 
Starting Time 
Point ( +2 
weeks)  Draw blood to record immunologic levels pre -booster #1  
Administer Booster #1   
x x x x x 2  
1 hr 
9 1 Month 9  
(+ 2 weeks)  Draw blood to record immunologic levels pre -booster #2  
Administer Booster #2   x x x x x 2 1 hr 
10 1 Month 12  
(+2 weeks)  Draw Blood for final Immunologic Sample  
Final Study Assessment   x x x x  0 1 hr 
 
Phase IIb TLPLDC & TLPO vaccine trial   Version 2.4/ 15 February 2021  
71 
 Appendix H  
 
Data Safety Monitoring Plan  
 
 
This is a free-standing  document  
Phase IIb TLPLDC & TLPO vaccine trial   Version 2.4/ 15 February 2021  
72 
  
Appendix I 
 
Adverse Events Reporting Algorithm  
 
 
 

Phase IIb TLPLDC & TLPO vaccine trial   Version 2.4/ 15 February 2021  
73 
  
Appendix J 
 
MedWatch FDA Form 3500 A Link 
  
Form FDA 3500A Link  
 
 
  
Phase IIb TLPLDC & I/IIa TLPO vaccine trial   Version 2.4/ 15 February 2021  
Confidential  74 Appendix K 
 
PROTOCOL TITLE:  A prospective, randomized, blinded, placebo -
controlled, phase IIb trial of an autologous tumor 
lysate (TL) + yeast cell wall particles (YCWP) + 
dendritic cells (DC) vaccine vs unloaded YCWP + 
DC and embedded phase I/IIa trial with tumor 
lysate particle onl y (TLPO) vaccine in stage III and 
stage IV (resected) melanoma to prevent 
recurrence  
 
PROTOCOL NUMBER:   20141932  
 
STUDY DRUG:  Autologous tumor lysate (TL) + yeast cell wall   
particles (YCWP) + dendritic cells (DC)  
 and 
 Autologous tumor lysate (TL) + yeast cell wall 
particles only (PO)  
 
PRINCIPAL INVESTIGATOR:  Mark B. Faries, MD, FACS  
 
PROGRAM DIRECTOR:   George E. Peoples, MD, FACS  
 
PROTOCOL VERSION/DATE:  2.4/ 15 February 2021 
 
INVESTIGATOR’S AGREEMENT / INVESTIGATOR’S SIGNATURE PAGE  
I have read the protocol described above. I have fully discussed the objectives of this 
trial and the content of this protocol with the sponsor or sponsor’s representative. I 
understand that the information in this protocol is confidential and should not b e 
disclosed, other than to those directly involved in the execution or the ethical review of 
the trial, without written authorization from Cancer Insight . It is, however, permissible to 
provide information to a patient in order to obtain consent.  I agree to conduct this trial 
according to the protocol and to comply with its requirements, subject to ethical and 
safety considerations and guidelines, and to conduct the trial in accordance with all 
applicable regulations, and guidelines as stated in the protoc ol and other information 
supplied to me. I understand that the sponsor may decide to suspend or prematurely 
terminate the trial at any time, for whatever reason. Such a decision will be 
communicated to me in writing. Conversely, should I decide to withdraw  from execution 
of the  trial, I will communicate my intention immediately, in writing to the Sponsor.  
 
 
Signed:       Date:                                                  
 
Investigator’s Name and Address:    
      
 
      
 
      
 
      